[{"role": "model", "parts": [{"text": "I am a large language model trained to be informative and comprehensive. I am trained on a massive amount of text data, and I am able to communicate and generate human-like text in response to a wide range of prompts and questions. For this task, I will act as a specialized assistant that can identify datasets mentioned in a publication and create a summary suitable for non-specialists.\n\nThe output should be a JSON array of objects, where each object has the following keys:\n- \"dataset_identifier\": This is any alphanumeric string (maybe including punctuation marks) that uniquely identifies or provides access to a dataset.\n- \"repository_reference\": This is the URL or reference to the data repository where the dataset can be found.\n\nHere are some examples for reference:\n\n['dataset_identifier'=> 'EGAS00001000925', 'repository_reference'=> 'https=>//ega-archive.org/datasets/EGAS00001000925',\n 'dataset_identifier'=> 'GSE69091', 'repository_reference'=> 'https=>//www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69091',\n 'dataset_identifier'=> 'PRJNA306801', 'repository_reference'=> 'https=>//www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA306801',\n 'dataset_identifier'=> 'phs003416.v1.p1', 'repository_reference'=> 'dbGaP',\n 'dataset_identifier'=> 'PXD049309', 'repository_reference'=> 'https=>//www.ebi.ac.uk/pride/archive/projects/PXD049309',\n 'dataset_identifier'=> 'IPX0004230000', 'repository_reference'=> 'http=>//www.iprox.org',\n 'dataset_identifier'=> 'MSV000092944', 'repository_reference'=> 'https=>//massive.ucsd.edu/',\n 'dataset_identifier'=> 'n/a', 'repository_reference'=> 'https://data.broadinstitute.org/ccle_legacy_data/mRNA_expression/'\n]"}]}, {"role": "user", "parts": [{"text": "I have a webpage in HTML format (<html class=\"\" lang=\"en\"> <head> <link href=\"/static/assets/style-b3a36f11.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-ef962842.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-3ade8b5c.css\" rel=\"stylesheet\"/> <link href=\"/static/img/favicons/apple-touch-icon.png\" rel=\"apple-touch-icon\" sizes=\"180x180\"/> <link href=\"/static/img/favicons/favicon-48x48.png\" rel=\"icon\" sizes=\"48x48\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-32x32.png\" rel=\"icon\" sizes=\"32x32\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-16x16.png\" rel=\"icon\" sizes=\"16x16\" type=\"image/png\"/> <link href=\"/static/img/favicons/site.webmanifest\" rel=\"manifest\"/> <link color=\"#0071bc\" href=\"/static/img/favicons/safari-pinned-tab.svg\" rel=\"mask-icon\"/> <title> Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors - PMC </title> <link href=\"https://www.google-analytics.com\" rel=\"preconnect\"/> <link href=\"https://cdn.ncbi.nlm.nih.gov\" rel=\"preconnect\"/> <link href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11062922/\" rel=\"canonical\"/> </head> <body> <a class=\"usa-skipnav\" href=\"#main-content\"> Skip to main content </a> <section aria-label=\"Official website of the United States government\" class=\"usa-banner\"> <div class=\"usa-accordion\"> <header class=\"usa-banner__header\"> <div class=\"usa-banner__inner\"> <div class=\"grid-col-auto\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__header-flag\" src=\"/static/img/us_flag.svg\"/> </div> <div aria-hidden=\"true\" class=\"grid-col-fill tablet:grid-col-auto\"> <p class=\"usa-banner__header-text\"> An official website of the United States government </p> <span class=\"usa-banner__header-action\"> Here's how you know </span> </div> <button aria-controls=\"gov-banner-default\" aria-expanded=\"false\" class=\"usa-accordion__button usa-banner__button\" type=\"button\"> <span class=\"usa-banner__button-text\"> Here's how you know </span> </button> </div> </header> <div class=\"usa-banner__content usa-accordion__content\" hidden=\"\" id=\"gov-banner-default\"> <div class=\"grid-row grid-gap-lg\"> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-dot-gov.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Official websites use .gov </strong> <br/> A <strong> .gov </strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-https.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Secure .gov websites use HTTPS </strong> <br/> A <strong> lock </strong> ( <span class=\"icon-lock\"> <svg aria-labelledby=\"banner-lock-description\" class=\"usa-banner__lock-image\" focusable=\"false\" height=\"64\" role=\"graphics-symbol\" viewbox=\"0 0 52 64\" width=\"52\" xmlns=\"http://www.w3.org/2000/svg\"> <title id=\"banner-lock-title\"> Lock </title> <desc id=\"banner-lock-description\"> Locked padlock icon </desc> <path d=\"M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z\" fill=\"#000000\" fill-rule=\"evenodd\"> </path> </svg> </span> ) or <strong> https:// </strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class=\"usa-overlay\"> </div> <header class=\"usa-header usa-header--extended usa-header--wide\"> <div class=\"ncbi-header\"> <div class=\"ncbi-header__container\"> <a class=\"ncbi-header__logo-container\" href=\"https://www.ncbi.nlm.nih.gov/\"> <img alt=\" NCBI home page \" class=\"ncbi-header__logo-image\" src=\"/static/img/ncbi-logos/nih-nlm-ncbi--white.svg\"/> </a> <button aria-label=\"Show menu\" class=\"usa-menu-btn ncbi-header__hamburger-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"ncbi-hamburger-icon\" fill=\"none\" focusable=\"false\" height=\"21\" viewbox=\"0 0 31 21\" width=\"31\" xmlns=\"http://www.w3.org/2000/svg\"> <path clip-rule=\"evenodd\" d=\"M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z\" fill=\"#F1F1F1\" fill-rule=\"evenodd\"> </path> </svg> </button> <div class=\"ncbi-header__desktop-buttons\"> <button aria-controls=\"search-field-desktop-navigation\" aria-expanded=\"false\" aria-label=\"Show search overlay\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> Search </button> <div class=\"ncbi-header__login-dropdown\"> <button aria-controls=\"login-dropdown-menu\" aria-expanded=\"false\" aria-label=\"Show login menu\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#person\"> </use> </svg> <span> Log in </span> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_less\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_more\"> </use> </svg> </button> <ul class=\"usa-nav__submenu ncbi-header__login-dropdown-menu\" hidden=\"\" id=\"login-dropdown-menu\"> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> <li class=\"usa-nav__submenu-item\"> <button class=\"usa-button usa-button--outline ncbi-header__login-dropdown-logout-button\" type=\"button\"> Log out </button> </li> </ul> </div> </div> </div> </div> <div class=\"ncbi-search-panel ncbi--show-only-at-desktop\" hidden=\"\"> <div class=\"ncbi-search-panel__container\"> <form action=\"https://www.ncbi.nlm.nih.gov/search/all/\" aria-describedby=\"search-field-desktop-navigation-help-text\" autocomplete=\"off\" class=\"usa-search usa-search--big ncbi-search-panel__form\" method=\"GET\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field-desktop-navigation\"> Search\u2026 </label> <input class=\"usa-input\" id=\"search-field-desktop-navigation\" name=\"term\" placeholder=\"Search NCBI\" type=\"search\" value=\"\"/> <button class=\"usa-button\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label=\"Primary navigation\" class=\"usa-nav\"> <p class=\"usa-sr-only\" id=\"primary-navigation-sr-only-title\"> Primary site navigation </p> <button aria-label=\"Close navigation menu\" class=\"usa-nav__close ncbi-nav__close-button\" type=\"button\"> <img alt=\"Close\" src=\"/static/img/usa-icons/close.svg\"/> </button> <form class=\"usa-search usa-search--small ncbi--hide-at-desktop margin-top-6\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field\"> Search </label> <input class=\"usa-input\" id=\"search-field-mobile-navigation\" name=\"search\" placeholder=\"Search NCBI\" type=\"search\"/> <button class=\"usa-button\" type=\"submit\"> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==\"/> </button> </form> <div class=\"ncbi-nav__mobile-login-menu ncbi--hide-at-desktop\" hidden=\"\"> <p class=\"ncbi-nav__mobile-login-menu-status\"> Logged in as: <strong class=\"ncbi-nav__mobile-login-menu-email\"> </strong> </p> <ul class=\"usa-nav__primary usa-accordion\"> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> </ul> </div> <button class=\"usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop\" type=\"button\"> Log in </button> </nav> </header> <section aria-label=\"PMC Header with search box\" class=\"pmc-header pmc-header--basic\"> <div class=\"pmc-nav-container\"> <div class=\"pmc-header__bar\"> <div class=\"pmc-header__logo\"> <a aria-label=\"PMC Home\" href=\"/\" title=\"Home\"> </a> </div> <button aria-label=\"Open search\" class=\"usa-button usa-button--unstyled pmc-header__search__button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__open\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__close\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"pmc-header__search\"> <form autocomplete=\"off\" class=\"usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form\" role=\"search\"> <label class=\"usa-sr-only\" for=\"pmc-search\"> Search PMC Full-Text Archive </label> <span class=\"autoComplete_wrapper flex-1\"> <input aria-autocomplete=\"both\" aria-controls=\"autoComplete_list_1\" aria-expanded=\"false\" aria-haspopup=\"true\" aria-owns=\"autoComplete_list_1\" class=\"usa-input width-full maxw-none\" id=\"pmc-search\" name=\"term\" placeholder=\"Search PMC Full-Text Archive\" required=\"required\" role=\"combobox\" type=\"search\"/> <ul aria-label=\"Suggestions\" hidden=\"\" id=\"autoComplete_list_1\" role=\"listbox\"> </ul> </span> <button class=\"usa-button\" formaction=\"https://www.ncbi.nlm.nih.gov/pmc/\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search in PMC </span> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"/static/img/usa-icons-bg/search--white.svg\"/> </button> </form> <ul class=\"pmc-header__search__menu\"> <li> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/advanced/\"> Advanced Search </a> </li> <li> <a class=\"usa-link\" href=\"/journals/\"> Journal List </a> </li> <li> <a class=\"usa-link\" href=\"/about/userguide/\"> User Guide </a> </li> </ul> </div> </div> </section> <div class=\"usa-section padding-top-0 desktop:padding-top-6 pmc-article-section\"> <div aria-label=\"Actions bar\" class=\"grid-container pmc-actions-bar is-not-intersecting\" role=\"complementary\"> <div class=\"grid-row\"> <div class=\"grid-col-fill display-flex\"> <div class=\"display-flex\"> <ul class=\"usa-list usa-list--unstyled usa-list--horizontal\"> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <button aria-label=\"Open resources\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#more_vert\"> </use> </svg> </button> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <span class=\"usa-tooltip\"> <a aria-label=\"View on publisher site\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"https://doi.org/10.1038/s41589-023-01459-3\" rel=\"noreferrer noopener\" role=\"button\" tabindex=\"0\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> View on publisher site </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <a aria-label=\"Download PDF\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"pdf/41589_2023_Article_1459.pdf\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Download PDF </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty usa-tooltip__trigger\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Add to Collections </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button usa-button--unstyled citation-dialog-trigger display-flex usa-tooltip__trigger\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Cite </span> </span> </li> <li class=\"pmc-permalink display-flex\"> <span class=\"usa-tooltip\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button usa-button--unstyled display-flex usa-tooltip__trigger\" tabindex=\"0\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Permalink </span> </span> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11062922/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </div> <button aria-label=\"Open article navigation\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#list\"> </use> </svg> </button> </div> </div> </div> <div class=\"grid-container desktop:padding-left-6\"> <div class=\"grid-row grid-gap\" id=\"article-container\"> <div class=\"grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content\"> <div class=\"grid-container padding-left-0 padding-right-0\"> <div class=\"grid-row desktop:margin-left-neg-6\"> <div class=\"grid-col-12\"> <div aria-label=\"Disclaimer note\" class=\"pmc-layout__disclaimer\" role=\"complementary\"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. <br/> Learn more: <a class=\"usa-link\" href=\"/about/disclaimer/\"> PMC Disclaimer </a> | <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright Notice </a> </div> </div> </div> <div class=\"grid-row pmc-wm desktop:margin-left-neg-6\"> <main class=\"usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0\" id=\"main-content\"> <section aria-label=\"Journal banner\" class=\"pmc-journal-banner text-center line-height-none\"> <img alt=\"Nature Portfolio logo\" height=\"75\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-npgopen.png\" usemap=\"#pmc-banner-imagemap\" width=\"500\"/> <map name=\"pmc-banner-imagemap\"> <area alt=\"Link to Nature Portfolio\" href=\"https://doi.org/10.1038/s41589-023-01459-3\" rel=\"noopener noreferrer\" shape=\"default\" target=\"_blank\" title=\"Link to Nature Portfolio\"/> </map> </section> <article lang=\"en\"> <section aria-label=\"Article citation and metadata\"> <section class=\"pmc-layout__citation font-secondary font-xs\"> <div> <div class=\"display-inline-block\"> <button aria-controls=\"journal_context_menu\" aria-expanded=\"false\" class=\"cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary\" type=\"button\"> Nat Chem Biol </button> </div> . 2023 Oct 30;20(5):577\u2013585. doi: <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41589-023-01459-3\" rel=\"noopener noreferrer\" target=\"_blank\"> 10.1038/s41589-023-01459-3 </a> </div> <nav hidden=\"hidden\" id=\"journal_context_menu\"> <ul class=\"menu-list font-family-ui\" role=\"menu\"> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/?term=%22Nat%20Chem%20Biol%22%5Bjour%5D\" role=\"menuitem\"> Search in PMC </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Nat%20Chem%20Biol%22%5Bjour%5D\" lang=\"en\" role=\"menuitem\"> Search in PubMed </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Nat%20Chem%20Biol%22%5BTitle%20Abbreviation%5D\" role=\"menuitem\"> View in NLM Catalog </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"?term=%22Nat%20Chem%20Biol%22%5Bjour%5D\" role=\"menuitem\"> Add to search </a> </li> </ul> </nav> </section> <section class=\"front-matter\"> <div class=\"ameta p font-secondary font-xs\"> <hgroup> <h1> Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors </h1> </hgroup> <div class=\"cg p\"> <a aria-describedby=\"id1\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Reinecke%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Maria Reinecke </span> </a> <div hidden=\"hidden\" id=\"id1\"> <h3> <span class=\"name western\"> Maria Reinecke </span> </h3> <div class=\"p\"> <sup> 1 </sup> Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany </div> <div class=\"p\"> <sup> 2 </sup> German Cancer Consortium (DKTK), partner site Munich and German Cancer Research Center (DKFZ), Heidelberg, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Reinecke%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Maria Reinecke </span> </a> </div> </div> <sup> 1, </sup> <sup> 2 </sup> , <a aria-describedby=\"id2\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Brear%20P%22%5BAuthor%5D\"> <span class=\"name western\"> Paul Brear </span> </a> <div hidden=\"hidden\" id=\"id2\"> <h3> <span class=\"name western\"> Paul Brear </span> </h3> <div class=\"p\"> <sup> 3 </sup> Department of Biochemistry, University of Cambridge, Cambridge, UK </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Brear%20P%22%5BAuthor%5D\"> <span class=\"name western\"> Paul Brear </span> </a> </div> </div> <sup> 3 </sup> , <a aria-describedby=\"id3\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Vornholz%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Larsen Vornholz </span> </a> <div hidden=\"hidden\" id=\"id3\"> <h3> <span class=\"name western\"> Larsen Vornholz </span> </h3> <div class=\"p\"> <sup> 4 </sup> Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany </div> <div class=\"p\"> <sup> 5 </sup> Center for Translational Cancer Research (TranslaTUM), Munich, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Vornholz%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Larsen Vornholz </span> </a> </div> </div> <sup> 4, </sup> <sup> 5 </sup> , <a aria-describedby=\"id4\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Berger%20BT%22%5BAuthor%5D\"> <span class=\"name western\"> Benedict-Tilmann Berger </span> </a> <div hidden=\"hidden\" id=\"id4\"> <h3> <span class=\"name western\"> Benedict-Tilmann Berger </span> </h3> <div class=\"p\"> <sup> 6 </sup> Structural Genomics Consortium, Buchmann Institute for Life Sciences, Goethe University Frankfurt, Frankfurt, Germany </div> <div class=\"p\"> <sup> 7 </sup> Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Berger%20BT%22%5BAuthor%5D\"> <span class=\"name western\"> Benedict-Tilmann Berger </span> </a> </div> </div> <sup> 6, </sup> <sup> 7 </sup> , <a aria-describedby=\"id5\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Seefried%20F%22%5BAuthor%5D\"> <span class=\"name western\"> Florian Seefried </span> </a> <div hidden=\"hidden\" id=\"id5\"> <h3> <span class=\"name western\"> Florian Seefried </span> </h3> <div class=\"p\"> <sup> 1 </sup> Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Seefried%20F%22%5BAuthor%5D\"> <span class=\"name western\"> Florian Seefried </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id6\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wilhelm%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Stephanie Wilhelm </span> </a> <div hidden=\"hidden\" id=\"id6\"> <h3> <span class=\"name western\"> Stephanie Wilhelm </span> </h3> <div class=\"p\"> <sup> 1 </sup> Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wilhelm%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Stephanie Wilhelm </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id7\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Samaras%20P%22%5BAuthor%5D\"> <span class=\"name western\"> Patroklos Samaras </span> </a> <div hidden=\"hidden\" id=\"id7\"> <h3> <span class=\"name western\"> Patroklos Samaras </span> </h3> <div class=\"p\"> <sup> 1 </sup> Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Samaras%20P%22%5BAuthor%5D\"> <span class=\"name western\"> Patroklos Samaras </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id8\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gyenis%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Laszlo Gyenis </span> </a> <div hidden=\"hidden\" id=\"id8\"> <h3> <span class=\"name western\"> Laszlo Gyenis </span> </h3> <div class=\"p\"> <sup> 8 </sup> Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario Canada </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gyenis%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Laszlo Gyenis </span> </a> </div> </div> <sup> 8 </sup> , <a aria-describedby=\"id9\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Litchfield%20DW%22%5BAuthor%5D\"> <span class=\"name western\"> David William Litchfield </span> </a> <div hidden=\"hidden\" id=\"id9\"> <h3> <span class=\"name western\"> David William Litchfield </span> </h3> <div class=\"p\"> <sup> 8 </sup> Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario Canada </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Litchfield%20DW%22%5BAuthor%5D\"> <span class=\"name western\"> David William Litchfield </span> </a> </div> </div> <sup> 8 </sup> , <a aria-describedby=\"id10\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22M%C3%A9dard%20G%22%5BAuthor%5D\"> <span class=\"name western\"> Guillaume M\u00e9dard </span> </a> <div hidden=\"hidden\" id=\"id10\"> <h3> <span class=\"name western\"> Guillaume M\u00e9dard </span> </h3> <div class=\"p\"> <sup> 1 </sup> Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22M%C3%A9dard%20G%22%5BAuthor%5D\"> <span class=\"name western\"> Guillaume M\u00e9dard </span> </a> </div> </div> <sup> 1 </sup> , <a aria-describedby=\"id11\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22M%C3%BCller%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Susanne M\u00fcller </span> </a> <div hidden=\"hidden\" id=\"id11\"> <h3> <span class=\"name western\"> Susanne M\u00fcller </span> </h3> <div class=\"p\"> <sup> 6 </sup> Structural Genomics Consortium, Buchmann Institute for Life Sciences, Goethe University Frankfurt, Frankfurt, Germany </div> <div class=\"p\"> <sup> 7 </sup> Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22M%C3%BCller%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Susanne M\u00fcller </span> </a> </div> </div> <sup> 6, </sup> <sup> 7 </sup> , <a aria-describedby=\"id12\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ruland%20J%22%5BAuthor%5D\"> <span class=\"name western\"> J\u00fcrgen Ruland </span> </a> <div hidden=\"hidden\" id=\"id12\"> <h3> <span class=\"name western\"> J\u00fcrgen Ruland </span> </h3> <div class=\"p\"> <sup> 2 </sup> German Cancer Consortium (DKTK), partner site Munich and German Cancer Research Center (DKFZ), Heidelberg, Germany </div> <div class=\"p\"> <sup> 4 </sup> Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany </div> <div class=\"p\"> <sup> 9 </sup> German Center for Infection Research (DZIF), partner site Munich, Munich, Germany </div> <div class=\"p\"> <sup> 5 </sup> Center for Translational Cancer Research (TranslaTUM), Munich, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ruland%20J%22%5BAuthor%5D\"> <span class=\"name western\"> J\u00fcrgen Ruland </span> </a> </div> </div> <sup> 2, </sup> <sup> 4, </sup> <sup> 9, </sup> <sup> 5 </sup> , <a aria-describedby=\"id13\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Hyv%C3%B6nen%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Marko Hyv\u00f6nen </span> </a> <div hidden=\"hidden\" id=\"id13\"> <h3> <span class=\"name western\"> Marko Hyv\u00f6nen </span> </h3> <div class=\"p\"> <sup> 3 </sup> Department of Biochemistry, University of Cambridge, Cambridge, UK </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Hyv%C3%B6nen%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Marko Hyv\u00f6nen </span> </a> </div> </div> <sup> 3 </sup> , <a aria-describedby=\"id14\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wilhelm%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Mathias Wilhelm </span> </a> <div hidden=\"hidden\" id=\"id14\"> <h3> <span class=\"name western\"> Mathias Wilhelm </span> </h3> <div class=\"p\"> <sup> 1 </sup> Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany </div> <div class=\"p\"> <sup> 10 </sup> Computational Mass Spectrometry, Technical University of Munich, Freising, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wilhelm%20M%22%5BAuthor%5D\"> <span class=\"name western\"> Mathias Wilhelm </span> </a> </div> </div> <sup> 1, </sup> <sup> 10 </sup> , <a aria-describedby=\"id15\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuster%20B%22%5BAuthor%5D\"> <span class=\"name western\"> Bernhard Kuster </span> </a> <div hidden=\"hidden\" id=\"id15\"> <h3> <span class=\"name western\"> Bernhard Kuster </span> </h3> <div class=\"p\"> <sup> 1 </sup> Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany </div> <div class=\"p\"> <sup> 2 </sup> German Cancer Consortium (DKTK), partner site Munich and German Cancer Research Center (DKFZ), Heidelberg, Germany </div> <div class=\"p\"> <sup> 11 </sup> Bavarian Biomolecular Mass Spectrometry Center (BayBioMS), Technical University of Munich, Freising, Germany </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuster%20B%22%5BAuthor%5D\"> <span class=\"name western\"> Bernhard Kuster </span> </a> </div> </div> <sup> 1, </sup> <sup> 2, </sup> <sup> 11, </sup> <sup> \u2709 </sup> </div> <ul class=\"d-buttons inline-list\"> <li> <button aria-controls=\"aip_a\" aria-expanded=\"false\" class=\"d-button\"> Author information </button> </li> <li> <button aria-controls=\"anp_a\" aria-expanded=\"false\" class=\"d-button\"> Article notes </button> </li> <li> <button aria-controls=\"clp_a\" aria-expanded=\"false\" class=\"d-button\"> Copyright and License information </button> </li> </ul> <div class=\"d-panels font-secondary-light\"> <div class=\"d-panel p\" id=\"aip_a\"> <div class=\"p\" id=\"Aff1\"> <sup> 1 </sup> Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany </div> <div id=\"Aff2\"> <sup> 2 </sup> German Cancer Consortium (DKTK), partner site Munich and German Cancer Research Center (DKFZ), Heidelberg, Germany </div> <div id=\"Aff3\"> <sup> 3 </sup> Department of Biochemistry, University of Cambridge, Cambridge, UK </div> <div id=\"Aff4\"> <sup> 4 </sup> Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany </div> <div id=\"Aff5\"> <sup> 5 </sup> Center for Translational Cancer Research (TranslaTUM), Munich, Germany </div> <div id=\"Aff6\"> <sup> 6 </sup> Structural Genomics Consortium, Buchmann Institute for Life Sciences, Goethe University Frankfurt, Frankfurt, Germany </div> <div id=\"Aff7\"> <sup> 7 </sup> Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany </div> <div id=\"Aff8\"> <sup> 8 </sup> Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario Canada </div> <div id=\"Aff9\"> <sup> 9 </sup> German Center for Infection Research (DZIF), partner site Munich, Munich, Germany </div> <div id=\"Aff10\"> <sup> 10 </sup> Computational Mass Spectrometry, Technical University of Munich, Freising, Germany </div> <div id=\"Aff11\"> <sup> 11 </sup> Bavarian Biomolecular Mass Spectrometry Center (BayBioMS), Technical University of Munich, Freising, Germany </div> <div class=\"author-notes p\"> <div class=\"fn\" id=\"_fncrsp93pmc__\"> <sup> \u2709 </sup> <p class=\"display-inline\"> Corresponding author. </p> </div> </div> </div> <div class=\"d-panel p\" id=\"anp_a\"> <div class=\"notes p\"> <section class=\"history\" id=\"historyarticle-meta1\"> <p> Received 2022 Jun 16; Accepted 2023 Sep 22; Issue date 2024. </p> </section> </div> </div> <div class=\"d-panel p\" id=\"clp_a\"> <div> \u00a9 The Author(s) 2023 </div> <p> <strong> Open Access </strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article\u2019s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article\u2019s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a class=\"usa-link usa-link--external\" href=\"https://creativecommons.org/licenses/by/4.0/\" rel=\"noopener noreferrer\" target=\"_blank\"> http://creativecommons.org/licenses/by/4.0/ </a> . </p> <div class=\"p\"> <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright notice </a> </div> </div> </div> <div> PMCID: PMC11062922 PMID: <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/37904048/\"> 37904048 </a> </div> </div> </section> </section> <section aria-label=\"Article content\"> <section class=\"body main-article-body\"> <section class=\"abstract\" id=\"Abs1\"> <h2> <a class=\"usa-anchor\" id=\"Abs1-anchor\"> </a> Abstract </h2> <p id=\"Par1\"> Medicinal chemistry has discovered thousands of potent protein and lipid kinase inhibitors. These may be developed into therapeutic drugs or chemical probes to study kinase biology. Because of polypharmacology, a large part of the human kinome currently lacks selective chemical probes. To discover such probes, we profiled 1,183 compounds from drug discovery projects in lysates of cancer cell lines using Kinobeads. The resulting 500,000 compound\u2013target interactions are available in ProteomicsDB and we exemplify how this molecular resource may be used. For instance, the data revealed several hundred reasonably selective compounds for 72 kinases. Cellular assays validated GSK986310C as a candidate SYK (spleen tyrosine kinase) probe and X-ray crystallography uncovered the structural basis for the observed selectivity of the CK2 inhibitor GW869516X. Compounds targeting PKN3 were discovered and phosphoproteomics identified substrates that indicate target engagement in cells. We anticipate that this molecular resource will aid research in drug discovery and chemical biology. </p> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <img alt=\"graphic file with name 41589_2023_1459_Figa_HTML.jpg\" class=\"graphic\" height=\"360\" id=\"d33e380\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/eb45c29a4f3d/41589_2023_1459_Figa_HTML.jpg\" width=\"708\"/> </p> <section class=\"kwd-group\" id=\"kwd-group1\"> <p> <strong> Subject terms: </strong> Proteomics, Kinases, Small molecules, Target identification </p> </section> </section> <section class=\"abstract\" id=\"Abs2\"> <hr class=\"headless\"/> <p id=\"Par3\"> Chemical proteomics profiling of 1,183 kinase inhibitors from past drug discovery projects revealed a large number of reasonably selective compounds for several kinases such as SYK and CK2. </p> </section> <section id=\"Sec1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"Sec1-anchor\"> </a> Main </h2> <p id=\"Par4\"> Kinase inhibitors have become important drugs, particularly in oncology. About 80 have been approved for use in humans and hundreds are investigated in clinical trials <sup> <a aria-describedby=\"CR1\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR1\"> 1 </a> </sup> . Most of these drugs show substantial polypharmacology, which may enhance their efficacy but may also result in undesired off-target liabilities <sup> <a aria-describedby=\"CR2\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR2\"> 2 </a> , <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> </sup> . Kinase inhibitors also play a major role as chemical probes in basic research, for example to explore the function of a particular kinase in a defined biological context or to validate it as a therapeutic target. To be able to attribute observed phenotypic or molecular effects of a compound to the inhibition of a particular kinase target, chemical probes must meet a series of stringent criteria including high potency, cellular activity and selectivity <sup> <a aria-describedby=\"CR4\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR4\"> 4 </a> \u2013 <a aria-describedby=\"CR6\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR6\"> 6 </a> </sup> . </p> <p id=\"Par5\"> Despite tremendous efforts in medicinal chemistry, many kinases still lack highly selective inhibitors and there are substantial errors in the literature regarding conclusions drawn from experiments using unselective compounds <sup> <a aria-describedby=\"CR7\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR7\"> 7 </a> , <a aria-describedby=\"CR8\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR8\"> 8 </a> </sup> . One way to overcome these issues is to use tool compounds with known selectivity profiles and broad annotation in several different assay panels <sup> <a aria-describedby=\"CR9\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR9\"> 9 </a> </sup> . To promote the development of such chemical probes and to foster research on kinases that have received little attention thus far, collections of well-characterized compounds have been assembled. This includes two versions of the published kinase inhibitor set (PKIS and PKIS2) from drug discovery programs of GlaxoSmithKline, Pfizer and Takeda <sup> <a aria-describedby=\"CR10\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR10\"> 10 </a> , <a aria-describedby=\"CR11\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR11\"> 11 </a> </sup> . Both sets have been widely distributed in the research community to crowd source assays that further characterize these molecules, to identify chemical starting points for the development of new chemical probes or to investigate kinase signaling. Because PKIS and PKIS2 still contain compounds that are too promiscuous or of insufficient potency to qualify as chemical probes, industrial and academic partners have teamed up to create the Kinase Chemogenomic Set (KCGS) comprising 187 small molecule kinase inhibitors <sup> <a aria-describedby=\"CR12\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR12\"> 12 </a> </sup> . All KCGS compounds show potent kinase inhibition and high selectivity when screened across a large panel of biochemical assays. A conceptually similar library has been assembled from peer-reviewed publications of projects performed at Hoffmann-La Roche Inc. However, none of the above compound sets has been investigated for selectivity on a proteome-wide scale. </p> <p id=\"Par6\"> We and others have shown that chemical proteomics approaches using immobilized kinase inhibitors (Kinobeads <sup> <a aria-describedby=\"CR13\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR13\"> 13 </a> , <a aria-describedby=\"CR14\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR14\"> 14 </a> </sup> , MIBs <sup> <a aria-describedby=\"CR15\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR15\"> 15 </a> </sup> ) or biotinylated acylphosphate probes (KiNativ <sup> <a aria-describedby=\"CR16\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR16\"> 16 </a> </sup> ) as affinity tools are an efficient and quantitative means to explain an inhibitors\u2019 target binding and selectivity profile under close-to-physiological conditions. Hence, the aim of the current study was (1) to characterize the target space and selectivity of the 1,183 published tool compounds assembled in the PKIS, PKIS2, KCGS and Roche collections, (2) to exemplify how these data may be used to identify potential new chemical probes, (3) to shed light on their mechanisms of action and (4) to share this resource of drug\u2013target interaction data with the scientific community to aid in drug discovery as well as chemical probe design for understudied kinases. </p> </section> <section id=\"Sec2\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"Sec2-anchor\"> </a> Results </h2> <section id=\"Sec3\"> <h3 class=\"pmc_sec_title\"> The target landscape of 1,183 tool compounds </h3> <p id=\"Par7\"> The four kinase inhibitor sets characterized here (PKIS, PKIS2, KCGS, Roche) comprise 1,183 nonredundant (111 duplicates) small molecules with drug-like physicochemical properties representing 64 chemotypes with high structural diversity (Fig. <a class=\"usa-link\" href=\"#Fig1\"> 1a </a> , Extended Data Fig. <a class=\"usa-link\" href=\"#Fig6\"> 1a </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM2\"> 1 </a> ). All compounds were subjected to Kinobead competition binding profiling at two concentrations (100 nM and 1 \u00b5M) and using a mixture of lysates from five cancer cell lines (K-562, COLO-205, MV-4-11, SK-N-BE(2) and OVCAR-8) to maximize the representation of endogenous proteins (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig6\"> 1b </a> , see \u2018Kinase inhibitor profiling with Kinobeads (Kinobeads pulldowns)\u2019 in <a class=\"usa-link\" href=\"#Sec9\"> Methods </a> section for details). Briefly, Kinobeads comprise seven broad-spectrum small molecule kinase inhibitors immobilized on Sepharose beads. This enables affinity enrichment of about 300 of the 555 human protein and lipid kinases as well as hundreds of further proteins from native cell lysates <sup> <a aria-describedby=\"CR13\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR13\"> 13 </a> , <a aria-describedby=\"CR14\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR14\"> 14 </a> , <a aria-describedby=\"CR17\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR17\"> 17 </a> </sup> (Fig. <a class=\"usa-link\" href=\"#Fig1\"> 1b </a> ). Compounds of interest are set to compete for target protein binding with Kinobeads in the lysate and the amount of a given protein bound to Kinobeads in the presence of a compound can be quantified relative to a dimethylsulfoxide (DMSO) vehicle control by label-free mass spectrometry. This assay measures the physical interaction of a compound with thousands of endogenous proteins in parallel and, when systematically increasing the concentration of competitor, enables the calculation of an apparent interaction constant ( <span id=\"IEq1\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"0\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> ) for each compound and protein. </p> <figure class=\"fig xbox font-sm\" id=\"Fig1\"> <h4 class=\"obj_head\"> Fig. 1. The target landscape of 1,184 kinase tool compounds. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig1_HTML.jpg\" target=\"_blank\"> <img alt=\"Fig. 1\" class=\"graphic zoom-in\" height=\"459\" id=\"d33e520\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/b9b9e140c9dc/41589_2023_1459_Fig1_HTML.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig1/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Small molecule kinase inhibitor libraries (including number of compounds in each library) used for Kinobeads profiling. <strong> b </strong> , Venn diagram of the number of kinases in the human genome, enriched by Kinobeads from mixed lysates and targeted by at least one inhibitor. Several metabolic kinases as well as nucleotide, FAD and heme binding proteins were also identified as kinase inhibitor binders. <strong> c </strong> , Windmill plot grouping compounds by library and the number of targets by Kinobeads. Compounds with potency below 100 nM are marked in gray. <strong> d </strong> , Number of compounds targeting a specific kinase with an affinity below 1 \u00b5M. Kinases are grouped by subfamilies and sorted alphabetically within each group. </p> </figcaption> </figure> <figure class=\"fig xbox font-sm\" id=\"Fig6\"> <h4 class=\"obj_head\"> Extended Data Fig. 1. Screening setup. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig6_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 1\" class=\"graphic zoom-in\" height=\"484\" id=\"d33e2216\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/ac12e1030e91/41589_2023_1459_Fig6_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig6/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Tool compounds were grouped into different chemotypes. The height of bars represents the number of compounds per chemotype. Representative structures of two chemotypes are given. Compound grouping was based on literature data. <strong> b </strong> , Schematic representation of the Kinobeads workflow used to profile drug-protein interactions. Cell lysates were equilibrated with DMSO, 100 nM or 1 \u00b5M of each drug. Kinobeads \u03b5 were used to enrich kinases and other proteins from lysates. Bead bound proteins were digested on-beads and peptides were measured by liquid chromatography-tandem MS. An automatic data analysis pipeline including a random forest classifier was used for peptide and protein identification and quantification, data processing and target annotation. </p> </figcaption> </figure> <p id=\"Par8\"> To enhance throughput, we investigated if two compound competitor concentrations (100 nM and 1 \u00b5M) are sufficient to determine <span id=\"IEq2\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"1\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> values. Therefore, 50 clinical kinase inhibitors were profiled with two inhibitor concentrations and the results were compared to full dose\u2013response data previously published for the same compounds <sup> <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> </sup> (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig7\"> 2a </a> and Supplementary Tables <a class=\"usa-link\" href=\"#MOESM2\"> 1 </a> and <a class=\"usa-link\" href=\"#MOESM3\"> 2 </a> ). We found good overall agreement between the two assays (Pearson\u2019s <em> r </em> = 0.808) but note that <span id=\"IEq3\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"2\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> values obtained from the two-dose data are only rough approximations, particularly for weak compound\u2013protein interactions and should, therefore, be treated with caution. </p> <figure class=\"fig xbox font-sm\" id=\"Fig7\"> <h4 class=\"obj_head\"> Extended Data Fig. 2. Screening controls. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig7_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 2\" class=\"graphic zoom-in\" height=\"367\" id=\"d33e2259\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/225cd25ffa64/41589_2023_1459_Fig7_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig7/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , p <em> K </em> <sub> d </sub> <sup> app </sup> values of targets of 50 clinical kinase inhibitors obtained with two doses were correlated to previously published results of full dose response (8 doses) Kinobeads experiments (Klaeger et al. <sup> <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> </sup> ). Each dot represents one drug-protein combination. Black line indicates a perfect correlation of 1. <strong> b </strong> , Unsupervised clustering of 98 Lestaurtinib pulldowns and their targets (color code reflects the p <em> K </em> <sub> d </sub> <sup> app </sup> of the drug protein interaction). <strong> c </strong> , Distribution of p <em> K </em> <sub> d </sub> <sup> app </sup> values for one of the indicated targets over 98 pulldown experiments. <strong> d </strong> , Performance of the random forest classifier used for target annotation was determined based on 98 Lestaurtinib Kinobeads pulldown experiments. Lestaurtinib has 76 targets according to Kinobeads screening data and numbers of false positives and false negatives were calculated. </p> </figcaption> </figure> <p id=\"Par9\"> Further adjustments to the published protocol included the reduction of the amount of protein extract per experiment to 2.5 mg of protein and to 17 \u00b5l of settled Kinobeads to enable higher throughput. Six DMSO vehicle controls were included in random order on every 96-well plate to allow data normalization within and across plates. We developed a data analysis pipeline including protein identification and quantification by MaxQuant/Andromeda <sup> <a aria-describedby=\"CR18\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR18\"> 18 </a> </sup> , calculation of half-maximum inhibitory concentration (IC <sub> 50 </sub> ) and <span id=\"IEq4\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"3\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> values, creation of interaction plots and classification of proteins as targets (see <a class=\"usa-link\" href=\"#Sec9\"> Methods </a> section \u2018Data analysis of Kinobeads pulldowns for details\u2019) <sup> <a aria-describedby=\"CR19\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR19\"> 19 </a> </sup> . Briefly, we used a random forest classifier for target annotation that was trained on residual binding of proteins to beads, the number of peptides identified for a given protein, the number tandem mass spectra that gave rise to these identifications and intensity variations within the DMSO controls. </p> <p id=\"Par10\"> To assess the reproducibility of the assay, triplicates of the tyrosine kinase inhibitor lestaurtinib were included in each 96-well plate. Lestaurtinib was chosen because it has 76 targets in the Kinobead assay that span a large range of affinities. Most targets were identified with similar affinities in each of the 98 lestaurtinib experiments indicating good intraplate and interplate reproducibility of the assay (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig7\"> 2b,c </a> ). More specifically, we measured a false positive rate of 0.16% and a false negative rate of 6.8% leading to an overall assay performance of 93.2% sensitivity and 99.8% specificity (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig7\"> 2d </a> ). </p> <p id=\"Par11\"> A total of 235 kinases were targeted by at least one inhibitor (Fig. <a class=\"usa-link\" href=\"#Fig1\"> 1b </a> ) and 226 kinases showed submicromolar affinity for at least one compound. The number of targets per compound varied greatly between compounds (one to more than 100) and this was observed for all four libraries (Fig. <a class=\"usa-link\" href=\"#Fig1\"> 1c </a> ). No targets could be identified for 67 compounds and a further 194 compounds had no target with submicromolar affinity. Only compound\u2013target interactions with nanomolar affinity were considered for all further analysis because the affinity data are not reliable beyond the highest dose in the assay (1,000 nM). Hierarchical clustering of compounds ( <em> n </em> = 833) and their respective protein kinase targets ( <em> n </em> = 226) revealed 5,341 nanomolar interactions illustrating that about half of the kinome can be drugged by the compound set analyzed here (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig8\"> 3a </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM3\"> 2 </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"Fig8\"> <h4 class=\"obj_head\"> Extended Data Fig. 3. The target landscape of 1,184 tool compounds. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig8_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 3\" class=\"graphic zoom-in\" height=\"625\" id=\"d33e2301\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/7fdc3d9e516f/41589_2023_1459_Fig8_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig8/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Hierarchical clustering of Kinobeads direct binders against 1,184 tool compounds. Each square represents one compound-target interaction and the color reflects the affinity of the interaction. <strong> b </strong> , Correlation of inhibition data of PKIS derived from Elkins et al. <sup> <a aria-describedby=\"CR10\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR10\"> 10 </a> </sup> against binding data of the Kinobeads screen. Each dot represents one drug-target pair. Dots on x- and y- axis were only identified as targets in one of the screens. <strong> c </strong> , Correlation of inhibition data of PKIS2 derived from Drewry et al. <sup> <a aria-describedby=\"CR11\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR11\"> 11 </a> </sup> to the binding data of the Kinobeads screen. Each dot represents one drug-target pair. Dots on x- and y- axis were only identified as targets in one of the screens. <strong> d </strong> , Correlation of inhibition data of PKIS derived from Elkins et al. <sup> <a aria-describedby=\"CR10\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR10\"> 10 </a> </sup> against binding data of the Kinobeads screen only for the cognate target of designated CDK2, EGFR, GSK and MAPK14 inhibitors. Each dot represents one drug-target pair. Dots on x- and y- axis were only identified as targets in one of the screens. Goodness of fit (R values) for each compound group as well as the overall correlation are displayed. <strong> e </strong> , Radar plot displays compounds that bind to ACOX1 (each spike is a drug and the length correspond to the affinity of the interaction). Right panel shows dose dependent intensity reduction of ACOX1 with increasing concentrations of GW775608X. Mean values +/\u2212s.e.m. of <em> n </em> = 6 DMSO control pulldown experiments are shown. </p> </figcaption> </figure> <p id=\"Par12\"> We found a poor overall correlation (Pearson\u2019s <em> r </em> = 0.385 and <em> r </em> = 0.302) between the two-dose affinity data from Kinobeads and published single-dose enzymatic inhibition data using recombinant kinase assays (Nanosyn and KINOMEscan) for PKIS and PKIS2 (refs. <sup> <a aria-describedby=\"CR10\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR10\"> 10 </a> , <a aria-describedby=\"CR11\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR11\"> 11 </a> </sup> ) (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig8\"> 3b,c </a> ). The correlations were often better when considering the designated targets of the tool compounds only (Pearson\u2019s <em> r </em> = 0.484\u20130.674; Extended Data Fig. <a class=\"usa-link\" href=\"#Fig8\"> 3d </a> ). The reasons for such apparent discrepancies between assays have been discussed before and can be explained by the multitude of different assay conditions including ATP concentrations, activities of native versus recombinant proteins, presence versus absence of cellular cofactors and complex partners or posttranslational modification of kinases and so on, all of which may affect binding and/or activity <sup> <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> , <a aria-describedby=\"CR20\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR20\"> 20 </a> </sup> (see \u2018Discussion\u2019). </p> <p id=\"Par13\"> The four compound sets targeted a broad range of kinases from all subfamilies with a slight overrepresentation of tyrosine kinases and CMGC kinases (Fig. <a class=\"usa-link\" href=\"#Fig1\"> 1d </a> ). This may be rooted in the fact that early kinase drug discovery often focused on the same few kinases. The most frequently targeted kinases were GSK3A, MAPK14, GAK, RIPK2 and RET with more than 100 compounds each. GAK and RET were particularly frequently hit even though very few compounds of the libraries analyzed were specifically designed to target either of the two proteins. Very similar observations have been made using Nanosyn and KINOMEscan assays <sup> <a aria-describedby=\"CR10\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR10\"> 10 </a> , <a aria-describedby=\"CR11\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR11\"> 11 </a> </sup> . In addition to kinases, Kinobeads also bind hundreds of other proteins, offering the possibility to discover unexpected interactions. Specific such interactions were identified for 16 nucleotide binding (nonkinase) proteins, five flavin adenine dinucleotide (FAD) binding proteins, two heme binding proteins and four metabolic kinases (Fig. <a class=\"usa-link\" href=\"#Fig1\"> 1b </a> ). Examples include the known off-targets NQO2 (ref. <sup> <a aria-describedby=\"CR21\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR21\"> 21 </a> </sup> ) and FECH <sup> <a aria-describedby=\"CR22\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR22\"> 22 </a> </sup> , and novel cases such as the FAD binding proteins ACOX1 and NQO1 (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig8\"> 3e </a> ). </p> </section> <section id=\"Sec4\"> <h3 class=\"pmc_sec_title\"> Selectivity of kinase inhibitor tool compounds </h3> <p id=\"Par14\"> Selectivity is a major characteristic for the designation of a kinase inhibitor as a chemical probe and we have introduced a selectivity metric called CATDS (concentration and target dependent selectivity) that provides a more accurate measure of selectivity than merely counting the number of targets at a particular drug concentration <sup> <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> , <a aria-describedby=\"CR23\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR23\"> 23 </a> </sup> . We note that the use of the term \u2018selectivity\u2019 throughout this manuscript solely refers to proteins that can be assayed by Kinobeads. CATDS <sub> most potent </sub> equates to the half-maximal engagement of the most potent compound\u2013target interaction divided by the sum of all target engagements of the compound at that concentration. CATDS scores near one indicate very selective compounds regardless of which protein they target (Fig. <a class=\"usa-link\" href=\"#Fig2\"> 2a </a> , for example, ERK5-IN-1 or GW869810X) and values near zero correspond to unselective compounds (for example, GSK1269851A; Supplementary Table <a class=\"usa-link\" href=\"#MOESM4\"> 3 </a> ). CATDS analysis showed that KCGS comprised the largest fraction of selective inhibitors (Fig. <a class=\"usa-link\" href=\"#Fig2\"> 2b </a> ) but still contained several broad-spectrum compounds including XMD-17-51 that bound to almost 50 proteins (Supplementary Table <a class=\"usa-link\" href=\"#MOESM3\"> 2 </a> ). Assembling the Kinobeads data into a compound\u2013target selectivity matrix revealed several clusters of selective inhibitors for a specific kinase (for example, epidermal growth factor receptor (EGFR); Extended Data Fig. <a class=\"usa-link\" href=\"#Fig9\"> 4a </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM4\"> 3 </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"Fig2\"> <h4 class=\"obj_head\"> Fig. 2. Selectivity of kinase tool compounds and potential chemical probes. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig2_HTML.jpg\" target=\"_blank\"> <img alt=\"Fig. 2\" class=\"graphic zoom-in\" height=\"395\" id=\"d33e744\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/ac00f343ba23/41589_2023_1459_Fig2_HTML.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig2/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Selectivity ranking of tool compounds (according to the compound-centric selectivity score, CATDS <sub> mostpotent </sub> ) highlighting ERK5-IN-1 and GW869810X as selective and GSK1269851A as unselective inhibitors. <strong> b </strong> , Distribution of the number of tool compounds over categories of selectivity. <strong> c </strong> , Phylogenetic tree of kinases marking kinases for which chemical probes have been identified in this study (blue and red). Blue circles represent kinases for which chemical probes have been reported before. </p> </figcaption> </figure> <figure class=\"fig xbox font-sm\" id=\"Fig9\"> <h4 class=\"obj_head\"> Extended Data Fig. 4. Identification of potential chemical probes. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig9_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 4\" class=\"graphic zoom-in\" height=\"666\" id=\"d33e2357\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/9660872e96fb/41589_2023_1459_Fig9_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig9/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , The CATDS <sub> target </sub> score of all 1,184 tool compounds and their corresponding direct binder targets are assembled in a drug/target interaction matrix using unsupervised clustering. Several clusters are highlighted in boxes. <strong> b </strong> , High resolution phylogenetic tree of Fig. <a class=\"usa-link\" href=\"#Fig2\"> 2 </a> with labels of all kinases. Blue circles represent kinases for which chemical probes have been reported before. <strong> c </strong> , Violin plots comparing the potency and selectivity of EGFR inhibitors that were identified as chemical probes in this study. p <em> K </em> <sub> d </sub> <sup> app </sup> values of EGFR are marked as black dots. The shape of the violin indicates the number of targets at the respective p <em> K </em> <sub> d </sub> <sup> app </sup> and the color reflexed the selectivity for EGFR. The total number of targets is printed at the top. The white dots represent the median of the data, the black boxes represent the first and third quartiles. Violins are colored according to selectivity for EGFR (CATDS <sub> EGFR </sub> ). <strong> d-f </strong> , Radar plots depicting proteins that bind to PFE-PKIS39 <strong> d </strong> , RO0272148-000 <strong> e </strong> or GW459057A <strong> f </strong> . Each spike is one protein target and the length corresponds to the affinity of the interaction. </p> <p> <a class=\"usa-link\" href=\"#MOESM8\"> Source data </a> </p> </figcaption> </figure> <p id=\"Par15\"> Next, we mined the data set for new potential chemical probes. These must meet certain criteria in terms of selectivity and target engagement <sup> <a aria-describedby=\"CR4\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR4\"> 4 </a> </sup> . For the Kinobeads data, these criteria were translated as follows: affinity ( <span id=\"IEq5\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"4\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> &lt; 1 \u00b5M) and CATDS <sub> most potent </sub> &gt; 0.5. An additional and important aspect is to account for targets outside the kinase space. For instance, ERK5-IN-1 is a selective compound in the Kinobead assay. However, the reported pharmacology in cells is mainly due to inhibition of BRD4 that cannot be detected by Kinobeads <sup> <a aria-describedby=\"CR24\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR24\"> 24 </a> </sup> . Because a full assessment of all potential targets of a compound is not possible, we limit the scope of any compound mentioned below to that of a \u2018probe candidate\u2019. </p> <p id=\"Par16\"> About 330 kinase inhibitors fulfilled these criteria and they target 72 kinases from all kinase subfamilies (Fig. <a class=\"usa-link\" href=\"#Fig2\"> 2c </a> , Extended Data Fig. <a class=\"usa-link\" href=\"#Fig9\"> 4b </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM4\"> 3 </a> ). At the time of writing, the portal chemicalprobes.org (ref. <sup> <a aria-describedby=\"CR25\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR25\"> 25 </a> </sup> ) listed 123 compounds targeting 133 human protein kinases (April 2022) of which 74 compounds targeting 89 kinases were endorsed for use as specific and selective modulator of the respective target. Our data contribute compounds for an additional 43 kinases. The current work also identified probe candidates for 29 kinases that already had such designated molecules (Fig. <a class=\"usa-link\" href=\"#Fig2\"> 2c </a> blue circles). The compound set investigated by Kinobeads here, contained 11 previous chemical probes. Only one (GSK583) also fulfilled our criteria and one other ( <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/protein/CCT24474\" rel=\"noopener noreferrer\" target=\"_blank\"> CCT24474 </a> ) barely missed the chosen threshold (CATDS <sub> CHECK1 </sub> 0.46). For four compounds (CCT251545, FM-381, GSK481, NVS-PAK1-1), the designated target could not be enriched by Kinobeads or it was not expressed in the cell lines used. A further four compounds (GNF-5, THZ1 and THZ531, NVP-2) failed to reveal their targets. This may be due to slow binding of the covalent inhibitors THZ1 (ref. <sup> <a aria-describedby=\"CR26\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR26\"> 26 </a> </sup> ) and (presumably) THZ531. For allosteric binder GNF-5, failure to detect BCR-ABL competition is not clear. The Kinobeads technology typically only scores ATP-competitive inhibitors unless allosteric compounds alter the ATP pocket conformation in a way that makes it inaccessible for the affinity resin (for example, observed for the AKT inhibitor MK2206, ref. <sup> <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> </sup> ). However, alternative displacement assays using bioluminescence resonance energy transfer (BRET) and time-resolved fluorescence energy transfer as readouts have detected the interaction <sup> <a aria-describedby=\"CR27\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR27\"> 27 </a> , <a aria-describedby=\"CR28\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR28\"> 28 </a> </sup> . For NVP-2, it is also not clear why CDK9 was not detected because many other compounds were. Because all identified off-targets did not pass the affinity threshold, an assessment of selectivity is not possible from the results obtained here. WZ4003 had poor selectivity in the Kinobeads assay and should, therefore, only be used with caution and including appropriate controls. </p> <p id=\"Par17\"> The Kinobead profiling data revealed probe candidates for well-studied kinases as well as understudied kinases. For this assessment, a target-centric version of CATDS can be used, which is calculated in an analogous fashion as the score of the most potent target (\u2018CATDS score\u2019 section). The largest number of candidates (37 compounds) were detected for the well-studied kinase EGFR, reflecting the strong medicinal chemistry efforts over the years for this important target (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig9\"> 4c </a> ). We also found selective compounds for the clinically relevant drug targets MET and FLT3 (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig9\"> 4d,e </a> ), including RO0272148-000 as a potent ( <span id=\"IEq6\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"5\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> = 99 nM) and selective (CADTS <sub> FLT3 </sub> = 0.87) FLT3 inhibitor. We note that even though several FLT3 inhibitors are approved drugs, these are not good tools for basic research on FLT3 as they often target many other proteins. The only off-target of RO0272148-000 in the Kinobead assay was ACOX1 ( <span id=\"IEq7\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"6\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> = 1,158 nM), the first enzyme of the fatty acid beta-oxidation pathway. To what extent this off-target binding is biologically relevant, remains to be investigated. We also discovered several selective EPHB6 binders. EPHB6 is a pseudokinase and modulates cell adhesion and migration when stimulated by ephrin-B2 (ref. <sup> <a aria-describedby=\"CR29\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR29\"> 29 </a> </sup> ). It is unclear how ATP-competitive small molecules would modulate nonenzymatic functions of pseudokinases but with selective molecules such as GW459057A ( <span id=\"IEq8\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"7\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> = 162 nM) in hand, this biology may be further explored (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig9\"> 4f </a> ). In addition, the molecule may serve as a warhead for the development of proteolysis targeting chimeras against EPHB6. This is interesting as pseudokinases are gaining interest in drug discovery owing to their physiological roles associated with various human diseases <sup> <a aria-describedby=\"CR30\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR30\"> 30 </a> </sup> . </p> </section> <section id=\"Sec5\"> <h3 class=\"pmc_sec_title\"> GSK986310C is a potent and selective SYK inhibitor </h3> <p id=\"Par18\"> The spleen tyrosine kinase (SYK) has been validated as a target for the treatment of a number of hematological cancers, autoimmune disorders and other inflammatory conditions <sup> <a aria-describedby=\"CR31\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR31\"> 31 </a> , <a aria-describedby=\"CR32\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR32\"> 32 </a> </sup> . Several SYK inhibitors (for example, fostamatinib, entospletinib and TAK659) are approved drugs or under evaluation in clinical trials <sup> <a aria-describedby=\"CR33\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR33\"> 33 </a> </sup> . According to previous Kinobeads profiling results, fostamatinib, its active metabolite and TAK659 bound many other proteins beside SYK (Fig. <a class=\"usa-link\" href=\"#Fig3\"> 3a </a> and published data <sup> <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> </sup> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM3\"> 2 </a> ). Hence, these SYK inhibitors are of insufficient quality to function as chemical probes to study the cellular function of the protein. By contrast, entospletinib had fewer targets but SYK was not the most potently inhibited protein (Fig. <a class=\"usa-link\" href=\"#Fig3\"> 3a,b </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM3\"> 2 </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"Fig3\"> <h4 class=\"obj_head\"> Fig. 3. GSK986310C is a probe candidate for SYK. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig3_HTML.jpg\" target=\"_blank\"> <img alt=\"Fig. 3\" class=\"graphic zoom-in\" height=\"430\" id=\"d33e953\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/658b6b8da257/41589_2023_1459_Fig3_HTML.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig3/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Radar plots depicting the targets and binding affinities of the tool compound GSK986310C and the two clinical SYK inhibitors entospletinib and TAK659. Each spike represents one target and its length corresponds to the affinity of the compound\u2013protein interaction. <strong> b </strong> , Chemical structures of GSK986310C and entospletinib. <strong> c </strong> , Schematic representation of the cytokine secretion assay in primary murine BMDCs. <strong> d </strong> , Enzyme-linked immunosorbent assays showing dose-dependent reduction of IL-10 levels in response to GSK986310C, entospletinib and TAK659. Data are presented as mean values \u00b1 s.e.m. of <em> n </em> = 3 biological replicates. <strong> e </strong> , Western blot readout of phospho-SYK (Tyr525/525) in BMDCs treated with inhibitors after 30 min of Zymosan stimulation. One out of three biological replicates is shown. </p> <p> <a class=\"usa-link\" href=\"#MOESM7\"> Source data </a> </p> </figcaption> </figure> <p id=\"Par19\"> Mining the Kinobeads data identified GSK986310C as a rather selective and potent SYK binder (CATDS <sub> SYK </sub> = 0.51; <span id=\"IEq9\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"8\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> = 80 nM; Fig. <a class=\"usa-link\" href=\"#Fig3\"> 3a,b </a> ). A subsequent full dose\u2013response experiment confirmed potent and selective binding to SYK ( <span id=\"IEq10\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"9\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> = 58 nM, CATDS <sub> SYK </sub> = 0.60; Extended Data Fig. <a class=\"usa-link\" href=\"#Fig10\"> 5a,b </a> ). Several much weaker binders (more than ten times weaker than SYK) did not confirm in the dose\u2013response analysis indicating that low affine targets are less reproducible in the assay. To confirm that SYK binding translates into target engagement and modulation of SYK activity in cells, we subjected GSK986310C, TAK659 and entospletinib to IL-10 secretion assay using murine primary bone marrow-derived dendritic cells (BMDCs) following Zymosan stimulation. One of the effects of Zymosan is that it activates Dectin-1 signaling, in turn activating SYK and leading to increased IL-10 cytokine production (Fig. <a class=\"usa-link\" href=\"#Fig3\"> 3c </a> ) <sup> <a aria-describedby=\"CR34\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR34\"> 34 </a> </sup> . Treatment of cells with the respective SYK inhibitors before Zymosan stimulation indeed led to decreased levels of IL-10 in a dose-dependent fashion (Fig. <a class=\"usa-link\" href=\"#Fig3\"> 3d </a> ). To show that SYK target engagement in cells is responsible for this observation, we determined the phosphorylation status of SYK-Tyr525/526 within the ATP-binding pocket. In line with the cytokine readout, we observed a dose depended reduction of pTyr525/526 indicating SYK inhibition in live cells (Fig. <a class=\"usa-link\" href=\"#Fig3\"> 3e </a> and Extended Data Fig. <a class=\"usa-link\" href=\"#Fig10\"> 5c </a> ). The above data show that GSK986310C and entospletinib are SYK inhibitors in cells and we argue that they should be used alongside each other as a chemical probe set to ascertain that any effects these molecules may have on cells, can indeed be attributed to the inhibition of SYK (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig10\"> 5d </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"Fig10\"> <h4 class=\"obj_head\"> Extended Data Fig. 5. Selective SYK inhibitors. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig10_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 5\" class=\"graphic zoom-in\" height=\"509\" id=\"d33e2380\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/6c6802e2590a/41589_2023_1459_Fig10_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig10/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Dose response curve of the Kinobeads competition experiment with GSK986310C for SYK. <strong> b </strong> , Heat map representing the target space of GSK986310C obtained by two dose and eight dose Kinobeads assay. Color code reflects the affinity of the compound:protein interaction. <strong> c </strong> , Western blot readout of phospho-SYK (Tyr525/525) in BMDCs treated with inhibitors after 30 min of Zymosan stimulation. Here biological replicate 2 and 3 are shown. <strong> d </strong> , Venn diagram showing the overlap of GSK986310C and Entospletinib targets. SYK is the only shared target of the two inhibitors. </p> </figcaption> </figure> </section> <section id=\"Sec6\"> <h3 class=\"pmc_sec_title\"> Selective inhibitors for CK2 </h3> <p id=\"Par20\"> CK2 is involved in the regulation of many cellular processes including cell growth, proliferation and death. The protein is often overexpressed in cancer cells and some become addicted to CK2 activity <sup> <a aria-describedby=\"CR35\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR35\"> 35 </a> , <a aria-describedby=\"CR36\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR36\"> 36 </a> </sup> . As a result, CK2 has emerged as an interesting target in oncology but very few molecules (for example, CX-4945) have made it to clinical trials so far. Although CX-4945 has been reported to be potent (confirmed by Kinobeads; <span id=\"IEq11\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"10\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> = 1 nM) and selective (CADTS <sub> CK2 </sub> = 0.89), several studies report off-target effects mediated by other proteins <sup> <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> , <a aria-describedby=\"CR37\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR37\"> 37 </a> </sup> . Our Kinobeads profiling data contained 64 CK2 binders some of which showed very high affinity and selectivity (Fig. <a class=\"usa-link\" href=\"#Fig4\"> 4a </a> and Supplementary Tables <a class=\"usa-link\" href=\"#MOESM3\"> 2 </a> and <a class=\"usa-link\" href=\"#MOESM4\"> 3 </a> ). Among these, 25 represent the quinolinyl-methylene-thiazolinone chemotype, originally optimized for CDK1 inhibition and leading to the identification of the CDK1 inhibitor RO-3306 (ref. <sup> <a aria-describedby=\"CR38\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR38\"> 38 </a> </sup> ). From the Kinobead data, RO4613269-000, RO-4603632-000 and RO4493940-000 appeared to be selective CK2 binders (CATDS <sub> CK2 </sub> of 0.86, 0.73, 0.70) with nanomolar affinity ( <span id=\"IEq12\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"11\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> of 58, 279 and 291 nM, respectively, Fig. <a class=\"usa-link\" href=\"#Fig4\"> 4a </a> and Extended Data Fig. <a class=\"usa-link\" href=\"#Fig11\"> 6a </a> ). Since members of this chemotype had not been comprehensively profiled for kinases before, it was not known that compounds of this chemotype can bind CK2. Inhibition of CK2 activity by all three compounds was confirmed using recombinant activity assays that showed very good correspondence with the Kinobeads binding data (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig11\"> 6b,c </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM5\"> 4 </a> ). None of the three compounds showed potent inhibition of CDK1 binding or activity, which agrees with published data <sup> <a aria-describedby=\"CR39\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR39\"> 39 </a> </sup> . </p> <figure class=\"fig xbox font-sm\" id=\"Fig4\"> <h4 class=\"obj_head\"> Fig. 4. Selective and potent CK2 inhibitors. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig4_HTML.jpg\" target=\"_blank\"> <img alt=\"Fig. 4\" class=\"graphic zoom-in\" height=\"465\" id=\"d33e1167\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/73d0e05e964e/41589_2023_1459_Fig4_HTML.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig4/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Scatter plot of selectivity (CATDS <sub> CK2 </sub> ) and affinity ( <span id=\"IEq13\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"12\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> ) of CK2 inhibitors. Compounds of the quinolinyl-methylene-thiazolinone chemotype are marked in gray. <strong> b </strong> , Radar plot depicting the target space and binding affinities of GW869516X. <strong> c </strong> , Recombinant kinase activity assay of GW869516X for CDK1/cyclinB, CSNK2A1 and CSNK2A2. <strong> d </strong> , Crystal structure of the ATP pocket of CK2\u03b1 bound to GW869516X (PDB <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWE/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWE </a> , blue). The central fused ring interacts with the back of the ATP site and the hinge region, stacking between Met163 and Val66 that are marked in red. <strong> e </strong> , Crystal structure of the ATP pocket of CK2\u03b1 with GW869516X (PDB <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWE/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWE </a> , blue) and CX-4945 (PDB <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb3PE1/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 3PE1 </a> , purple) superimposed. The highly conserved residues Lys68, Asp175 and Glu81 within the ATP site are highlighted in green. <strong> f </strong> , Dose-dependent in-cell target engagement assays for CSNK2A1 and CSNK2A2 (NanoBRET in HEK293T cells) for GW869516X. One out of two biological replicates are shown. </p> </figcaption> </figure> <figure class=\"fig xbox font-sm\" id=\"Fig11\"> <h4 class=\"obj_head\"> Extended Data Fig. 6. Selective CK2 inhibitors. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig11_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 6\" class=\"graphic zoom-in\" height=\"574\" id=\"d33e2419\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/c6d61f35f26f/41589_2023_1459_Fig11_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig11/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Chemical structure of CK2 inhibitors. <strong> b </strong> , Kinase activity assays of the indicated compounds for CDK1/cyclinB, CSNK2A1 and CSNK2A2 validated the binding results obtained by Kinobeads. <strong> c </strong> , <em> K </em> <sub> d </sub> <sup> app </sup> and IC <sub> 50 </sub> values for CSNK2A1 and CSNK2A2 in Kinobeads screen (binding) and in recombinant kinase assays (activity). <strong> d </strong> , The highly conserved residues within the ATP site are highlighted (green) on the structure of RO4613269-000 (PDB:7A4Q; purple) bound to CK2\u03b1 with RO4493940-000 (PDB:7ZWG; green) superimposed. </p> </figcaption> </figure> <p id=\"Par21\"> Another potent and selective inhibitor for CK2 was GW869516X (CATDS <sub> CK2 </sub> of 1; <span id=\"IEq14\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"13\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> of 78 nM; IC <sub> 50 </sub> of 85 nM) representing an imidazotriazine chemotype unrelated to the RO-compound series (Fig. <a class=\"usa-link\" href=\"#Fig4\"> 4b,c </a> , Extended Data Fig. <a class=\"usa-link\" href=\"#Fig11\"> 6a,c </a> and Supplementary Tables <a class=\"usa-link\" href=\"#MOESM3\"> 2 </a> \u2013 <a class=\"usa-link\" href=\"#MOESM5\"> 4 </a> ). This was a surprising finding as a previous study reported more than 70% inhibition of binding of 33 kinases in a broad KINOMEscan assay (covering 468 kinases) for this compound. Only CSNK2A1 and CSNK2A2 were confirmed as targets using Kinobeads, 20 kinases showed no inhibition of binding and 11 kinases were not detected in the Kinobeads assay (Supplementary Table <a class=\"usa-link\" href=\"#MOESM5\"> 4 </a> ). The reasons for this discrepancy are currently not clear. </p> <p id=\"Par22\"> To investigate the structural basis for the observed selectivity of GW869516X (according to Kinobeads), we determined the crystal structure of CK2\u03b1 in complex with GW869516X (Protein Data Bank (PDB) <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWE/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWE </a> ). The structure clearly shows GW869516X binding in the ATP pocket of CK2\u03b1 (Fig. <a class=\"usa-link\" href=\"#Fig4\"> 4d </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM5\"> 4 </a> ). The central fused ring interacts with the back of the ATP site and the hinge region, stacking between Met163 and Val66. The indole group sits underneath Val53, projecting away from the pocket. The trimethoxybenzene group protrudes from the ATP site interacting with the end of the hinge region and the top of the \u03b1D loop. Examination of the structure of ATP site of a number of representative kinases indicated that a number of residues that cluster around Lys68 are highly conserved across a large number of kinases, whereas residues in the hinge region and around the top of the \u03b1D loop are less conserved <sup> <a aria-describedby=\"CR40\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR40\"> 40 </a> </sup> . GW869516X does not interact with the highly conserved Lys68 or its surrounding residues (Fig. <a class=\"usa-link\" href=\"#Fig4\"> 4e </a> ). Comparison with the binding mode of CX-4945 (PDB <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb3PE1/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 3PE1 </a> ) <sup> <a aria-describedby=\"CR41\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR41\"> 41 </a> </sup> highlighted the differences in the selectivity of the two compounds (Fig. <a class=\"usa-link\" href=\"#Fig4\"> 4e </a> ). As mentioned, CX-4945 has been shown in a number of studies to potently inhibit a large number of other kinases <sup> <a aria-describedby=\"CR37\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR37\"> 37 </a> </sup> . Indeed, the binding mode of CX-4945 to seven of these kinases has been determined crystallographically <sup> <a aria-describedby=\"CR42\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR42\"> 42 </a> \u2013 <a aria-describedby=\"CR44\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR44\"> 44 </a> </sup> . CX-4945 binds to all these kinases in a highly conserved binding mode that is dominated by its interaction with the conserved residue equivalent to Lys68 and this is likely the factor that drives its promiscuity. Likewise, when the binding modes of RO4493940-000 and RO4613269-000 (PDB <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWG/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWG </a> and <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7A4Q/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7A4Q </a> ) were determined by crystallography in the current study (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig11\"> 6d </a> ), they showed that the thiazole head group interacts with the conserved residue Lys68. These compounds, similar to CX-4945, showed inhibition of a few other kinases that is likely, in part, because of the interaction with Lys68. Of note, RO4493940-000 contains a rhodanine-like substructure and rhodanine is among a list of pan assay interference compounds (PAINS) <sup> <a aria-describedby=\"CR45\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR45\"> 45 </a> </sup> . However, the Kinobeads data do not indicate that RO4493940-000 is a promiscuous binder or that CK2 is a false positive hit. </p> <p id=\"Par23\"> CK2 target engagement by GW869516X in cells, was confirmed by NanoBRET assays resulting in IC <sub> 50 </sub> values of 446 and 319 nM for CK2A1 and CK2A2, respectively (Fig. <a class=\"usa-link\" href=\"#Fig4\"> 4f </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM5\"> 4 </a> ). GW869516X was less potent in NanoBRET versus Kinobead assays (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig11\"> 6c </a> ) likely because cells contain far higher ATP concentrations than lysates and the plasma membrane of the cell also constitutes a physical barrier. </p> </section> <section id=\"Sec7\"> <h3 class=\"pmc_sec_title\"> GSK902056A and GSK949675A are probe candidates for PKN3 </h3> <p id=\"Par24\"> The serine/threonine kinase PKN3 is an understudied kinase whose molecular function and downstream targets are largely unknown <sup> <a aria-describedby=\"CR46\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR46\"> 46 </a> </sup> . In recent studies, PKN3 has been functionally linked to metastasis, invasion and tumor growth making it a potential target for drug discovery in oncolgy <sup> <a aria-describedby=\"CR47\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR47\"> 47 </a> , <a aria-describedby=\"CR48\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR48\"> 48 </a> </sup> . A liposomal small interfering RNA (siRNA) (Atu027) against PKN3 is currently under investigation in clinical trials for solid tumors and pancreatic cancer <sup> <a aria-describedby=\"CR49\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR49\"> 49 </a> , <a aria-describedby=\"CR50\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR50\"> 50 </a> </sup> . In 2019, a covalent PKN3 inhibitor (JZ128) that targets Cys840 in PKN3 was reported <sup> <a aria-describedby=\"CR51\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR51\"> 51 </a> </sup> . JZ128 was developed based on the structure of THZ1, a CDK7 inhibitor with reported off-target binding to PKN3. In addition, a small, focused library of 4-anilinoquin(az)olines PKN3 inhibitors with cellular activity was reported. However, the described compounds had off-targets within the kinome and in-cell target engagement was rather low (1.3 \u00b5M) even for the most potent compound (UNC-CA94) <sup> <a aria-describedby=\"CR52\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR52\"> 52 </a> </sup> . Hence, there is a clear need for further selective and potent PKN3 inhibitors. </p> <p id=\"Par25\"> The Kinobeads data identified 49 PKN3 binders of which GSK902056A (CATDS <sub> PKN3 </sub> of 0.93; <span id=\"IEq15\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"14\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> of 1 nM) and GSK949675A (CATDS <sub> PKN3 </sub> of 0.86; <span id=\"IEq16\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"15\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> of 2.5 nM) stood out in terms of potency and selectivity (Fig. <a class=\"usa-link\" href=\"#Fig5\"> 5a </a> and Extended Data Fig. <a class=\"usa-link\" href=\"#Fig12\"> 7 </a> ). SB-476429-A is less selective but a useful control compound as it only shares PKN3 as a common target (CATDS <sub> PKN3 </sub> of 0.21; <span id=\"IEq17\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"16\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> of 36 nM; Fig. <a class=\"usa-link\" href=\"#Fig5\"> 5b </a> and Extended Data Fig. <a class=\"usa-link\" href=\"#Fig12\"> 7 </a> ). The two-dose Kinobeads data were confirmed by full dose\u2013response measurements ( <span id=\"IEq18\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"17\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> of 10, 90 and 38 nM for GSK902056A, GSK949675A and SB-476429-A, respectively; Extended Data Fig. <a class=\"usa-link\" href=\"#Fig12\"> 7f\u2013h </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM6\"> 5 </a> ) and the two measurements were well correlated (Pearson\u2019s <em> r </em> = 0.716, Extended Data Fig. <a class=\"usa-link\" href=\"#Fig12\"> 7i </a> ). Cellular target engagement of PKN3 binders was assessed by NanoBRET assays <sup> <a aria-describedby=\"CR28\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR28\"> 28 </a> </sup> and 14 of the 16 chosen compounds showed a dose-dependent reduction of the normalized BRET signal (Fig. <a class=\"usa-link\" href=\"#Fig5\"> 5c </a> , Extended Data Fig. <a class=\"usa-link\" href=\"#Fig13\"> 8 </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM6\"> 5 </a> ). Again, compounds were less potent in the NanoBRET than in the Kinobeads assay. Still, GSK902056A potently engaged PKN3 in cells with an IC <sub> 50 </sub> of 79 nM, GSK949675A with 136 nM and SB-476429-A with 85 nM and all three compounds showed higher levels of in-cell target engagement and a higher selectivity window than the reported compounds mentioned above <sup> <a aria-describedby=\"CR52\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR52\"> 52 </a> </sup> . Taken together, GSK902056A may be the current best in class PKN3 probe and may be a good starting point for further optimization to develop more potent PKN3 inhibitors in the future. </p> <figure class=\"fig xbox font-sm\" id=\"Fig5\"> <h4 class=\"obj_head\"> Fig. 5. Compounds targeting PKN3. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig5_HTML.jpg\" target=\"_blank\"> <img alt=\"Fig. 5\" class=\"graphic zoom-in\" height=\"484\" id=\"d33e1462\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/fa37b4cdeb8e/41589_2023_1459_Fig5_HTML.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig5/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Radar plot depicting compounds that bind PKN3 with a particular affinity. Each spike represents one compound and the length indicates the affinity of the interaction. <strong> b </strong> , Heat map illustrating the targets and affinities of three selected PKN3 inhibitors. <strong> c </strong> , Dose-dependent in-cell PKN3 target engagement assays (NanoBRET in HEK293T cells) for the same compounds as in <strong> b </strong> . One out of three biological replicates is shown. <strong> d </strong> , Venn diagram showing the number of regulated phosphorylation sites identified in RKO cells in response to 1 h treatment and 1 \u00b5M of the respective compounds or 48 h of siRNA-mediated PKN3 knockdown. Commonly regulated phosphorylation sites are shown in the text box. <strong> e </strong> , Examples for potential PKN3 substrates and their response to the conditions shown in <strong> d </strong> . Data are presented as mean values \u00b1 s.e.m. of <em> n </em> = 4 biological replicates. </p> </figcaption> </figure> <figure class=\"fig xbox font-sm\" id=\"Fig12\"> <h4 class=\"obj_head\"> Extended Data Fig. 7. Compounds targeting PKN3. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig12_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 7\" class=\"graphic zoom-in\" height=\"599\" id=\"d33e2472\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/7e34398e2822/41589_2023_1459_Fig12_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig12/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Selectivity of PKN3 inhibitors as obtained by the PKN3-specific CATDS <sub> PKN3 </sub> score. Inhibitors in the top right corner are the most potent and most selective PKN3 inhibitors within the screened panel. <strong> b </strong> , Chemical structure of three tool compounds that show binding to PKN3. <strong> c-e </strong> , Radarplots depicting the target space and binding affinities of the three PKN3 inhibitors ( <strong> c </strong> ) SB-476429-A, ( <strong> d </strong> ) GSK902056A and ( <strong> e </strong> ) GSK949675A. <strong> f-h </strong> , Full dose response curve of Kinobeads competition experiment with ( <strong> f </strong> ) SB-476429-A, ( <strong> g </strong> ) GSK902056A and ( <strong> h </strong> ) GSK949675A for PKN3. <strong> i </strong> , Correlation of <em> K </em> <sub> d </sub> <sup> app </sup> values obtained by two dose and eight dose Kinobeads pulldown experiment. </p> </figcaption> </figure> <figure class=\"fig xbox font-sm\" id=\"Fig13\"> <h4 class=\"obj_head\"> Extended Data Fig. 8. Cellular target engagement of PKN3 inhibitors. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig13_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 8\" class=\"graphic zoom-in\" height=\"714\" id=\"d33e2483\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/31ac86704465/41589_2023_1459_Fig13_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig13/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Dose dependent reduction of the BRET signal with increasing inhibitor concentrations were observed for eleven compounds indicating PKN3 target engagement in cells. One out of four biological replicates is shown. </p> </figcaption> </figure> <p id=\"Par26\"> To be able to measure PKN3 activity in cells, bona fide substrates of the kinase would be needed but no such substrate has been conclusively validated yet. In search for such candidates, we compared the phosphoproteomes of RKO cells (human colorectal cancer cells expressing high PKN3 levels according to ProteomicsDB <sup> <a aria-describedby=\"CR53\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR53\"> 53 </a> </sup> ) in response to the same three compounds (that only share PKN3 as a target), as well as THZ1 (a covalent inhibitor for which PKN3 is a reported off-target <sup> <a aria-describedby=\"CR51\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR51\"> 51 </a> </sup> ) and in response to siRNA-mediated knockdown of PKN3 (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig14\"> 9a,b </a> ). The analysis covered a total of 21,400 phosphorylation sites (p sites, Extended Data Fig. <a class=\"usa-link\" href=\"#Fig14\"> 9c </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM6\"> 5 </a> ) and showed that THZ1 and SB-476429-perturbed a large number of p sites, reflecting the engagement of many target kinases in cells. The respective numbers were far smaller for GSK949675A, GSK902056A (all four drugs used at 1 \u00b5M for 1 hour) or the siRNA experiment (48 h of knockdown; Fig. <a class=\"usa-link\" href=\"#Fig5\"> 5d </a> , Extended Data Fig. <a class=\"usa-link\" href=\"#Fig14\"> 9d </a> and Supplementary Table <a class=\"usa-link\" href=\"#MOESM6\"> 5 </a> ). Successful PKN3 knockdown (89 and 92% for 1 and 3 nM siRNA, respectively) was confirmed by parallel reaction monitoring (a quantitative mass spectrometry-based protein expression assay; Extended Data Fig. <a class=\"usa-link\" href=\"#Fig15\"> 10a </a> ). The reported activation loop p sites of PKN3 (S544 and T550) showed a marked reduction following PKN3 knockdown and a substantial reduction by SB-476429-A, but not by the other compounds (Extended Data Fig. <a class=\"usa-link\" href=\"#Fig15\"> 10b </a> ). Because the binding modes of GSK949675A, GSK902056A and SB-476429 are not known, the lack of A-loop phosphorylation reduction by the GSK compounds does not mean that PKN3 is not inhibited by the compounds. In line, THZ1 covalently binds to a Cys residue remote from the ATP pocket of PKN3 and which renders PKN3 inactive but it did not lead to a change in A-loop phosphorylation. </p> <figure class=\"fig xbox font-sm\" id=\"Fig14\"> <h4 class=\"obj_head\"> Extended Data Fig. 9. Phosphoproteome analysis of RKO cells in response to PKN3 inhibitors. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig14_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 9\" class=\"graphic zoom-in\" height=\"487\" id=\"d33e2506\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/b4085af7c029/41589_2023_1459_Fig14_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig14/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Schematic representation of the phosphoproteomic workflow (performed in four biological replicates). <strong> b </strong> , Venn diagram showing the overlap of the targets of three PKN3 inhibitors. PKN3 is the only shared target of the inhibitors. <strong> c </strong> , Number of identified phospho sites in four biological replicates. <strong> d </strong> , Volcano plots showing the extent and statistical significance of regulated phospho sites by four PKN3 inhibitors and PKN3 siRNA. Statistically significantly regulated phospho sites are marked in blue (two sided T-test, FDR = 0.01; s0 see material and methods). </p> </figcaption> </figure> <figure class=\"fig xbox font-sm\" id=\"Fig15\"> <h4 class=\"obj_head\"> Extended Data Fig. 10. Phosphoproteome analysis of RKO cells in response to PKN3 inhibitors. </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11062922_41589_2023_1459_Fig15_ESM.jpg\" target=\"_blank\"> <img alt=\"Extended Data Fig. 10\" class=\"graphic zoom-in\" height=\"329\" id=\"d33e2532\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d7a/11062922/e1810b328f30/41589_2023_1459_Fig15_ESM.jpg\" width=\"722\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/Fig15/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> <strong> a </strong> , Bar plot showing relative intensity of PKN3 peptides as monitored by a PRM assay. Six different peptides were monitored and sum peak areas of all fragment ions were used for analysis. Relative intensity of all six peptides were calculated and the mean value +/\u2212 s.e.m. are shown. Different siRNA concentrations were tested to knock down PKN3 in RKO cells. ( <strong> b </strong> ) Residual phosphorylation of PKN3 peptides after treatment of RKO cells with respective inhibitors or siRNA. Mean values +/\u2212 s.e.m. are shown. Error bars indicate standard deviations of <em> n </em> = 4 biological replicates are shown. ( <strong> c </strong> ) Residual phosphorylation of selected phospho sites. Error bars indicate mean values +/\u2212 s.e.m. of <em> n </em> = 4 biological replicates are displayed. </p> </figcaption> </figure> <p id=\"Par27\"> Seven p sites on seven different proteins were consistently down-regulated in all replicates ( <em> n </em> = 4) and treatment conditions making these the strongest candidates for direct or indirect targets of PKN3 in RKO cells (Fig. <a class=\"usa-link\" href=\"#Fig5\"> 5d,e </a> and Extended Data Fig. <a class=\"usa-link\" href=\"#Fig15\"> 10c </a> ). The reduction of pS104 on MARCKSL1 validated the approach because this site had previously been identified as a potential downstream target of PKN3 (ref. <sup> <a aria-describedby=\"CR51\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR51\"> 51 </a> </sup> ). In addition, six of the seven candidates were found to be PKN3 substrates in a very recent large-scale investigation of kinase\u2013substrate relationships <sup> <a aria-describedby=\"CR54\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR54\"> 54 </a> </sup> , three of which with extremely high confidence (greater than the 97th percentile). From this study, we constructed a PKN3 substrate motif and four of the seven candidates contain the central Ser-Phe residues making these the best candidates for direct PKN3 substrates (Supplementary Table <a class=\"usa-link\" href=\"#MOESM6\"> 5 </a> ). Clearly, further experiments are required to confirm PKN3 as the kinase responsible for these particular phosphorylation sites. </p> </section> </section> <section id=\"Sec8\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"Sec8-anchor\"> </a> Discussion </h2> <p id=\"Par28\"> In this study, we have generated a large resource of kinase\u2013drug interactions on the basis of nearly 1,200 compounds from medicinal chemistry efforts and the Kinobead chemical proteomics approach. The body of 500,000 drug\u2013protein interactions covers about 250 protein and lipid kinases and is available for further mining in ProteomicsDB <sup> <a aria-describedby=\"CR53\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR53\"> 53 </a> , <a aria-describedby=\"CR55\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR55\"> 55 </a> </sup> and we highlight a number of cases how this resource may be used. The analysis promotes about 350 potential probe candidates that can be further investigated and identified 40 kinases for which no chemical probes had been available yet. </p> <p id=\"Par29\"> While this chemical proteomics screen was overall very successful, it is not without its shortcomings. The Kinobead assay does not cover all kinases; hence it is possible, that the designated target of a compound cannot be identified. It is also possible that a chemical probe candidates is less (or more) selective than suggested by our data because Kinobeads assess target engagement in lysates not in cells. It is possible, that the cellular target engagement and selectivity of probe candidates is higher or lower than expected from the Kinobead profiles. The former may result from ATP concentrations being much higher in cells than in lysates or for targets that gain their cellular activity by forming protein complexes in cells (for example, CDKs, PI3Ks). The latter can arise from, for example, poor compound penetration or the activity of efflux pumps. We also note that the assay was not optimized for differences in binding kinetics of individual compound. The apparent interaction constants reported in this study may, therefore, not necessarily be accurate for slow binders such as histone deacetylase inhibitors (as a result of slow on-rates) or certain covalent compounds such as THZ1 (as a result of slow reaction). This can be easily addressed by performing Kinobead assays using different drug preincubation times but doing so was not feasible for more than 1,000 compounds. Similarly, systematic phosphoproteome profiling of all compounds may be one way to address cellular selectivity in more detail, but performing experiments on such a scale is not yet experimentally tractable. </p> <p id=\"Par30\"> It should be noted that more than half of the human kinome is still without chemical probes. In part, this is due to the limited set of kinases covered by the Kinobead assay but it is also very possible that the chemical space able to address human kinases is not yet comprehensive. Together with the fact that no compounds have been found for targeting many human kinases with a clear disease connotation warrant and require substantial further chemical biology and chemical proteomics efforts in the future. In light of recent advances in computational structural biology <sup> <a aria-describedby=\"CR56\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR56\"> 56 </a> </sup> we think that the data and online resource provided in this study add substantially to this important field of research. </p> </section> <section id=\"Sec9\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"Sec9-anchor\"> </a> Methods </h2> <section id=\"Sec10\"> <h3 class=\"pmc_sec_title\"> Affinity matrix and compounds </h3> <p id=\"Par31\"> PKIS and PKIS2 and KCGS were obtained from the Structural Genomics Consortium (SGC). The KCGS library can be requested here: <a class=\"usa-link usa-link--external\" href=\"https://www.sgc-unc.org/request-kcgs\" rel=\"noopener noreferrer\" target=\"_blank\"> https://www.sgc-unc.org/request-kcgs </a> (February 2023). The Roche library was provided by Hoffmann-La Roche AG (Basel) and is not commercially available. Clinical kinase inhibitors were purchased from commercial sources (Selleckchem, MedChemExpress, Active Biochem or LC Laboratories). Kinase inhibitor affinity matrices (Kinobeads \u03b5) were prepared in house as previously described <sup> <a aria-describedby=\"CR14\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR14\"> 14 </a> </sup> . </p> </section> <section id=\"Sec11\"> <h3 class=\"pmc_sec_title\"> Cell lines and lysis </h3> <p id=\"Par32\"> K-562 (chronic myeloid leukemia), COLO-205 (colon cancer) and MV-4-11 (acute monocytic leukemia) cells were cultured in Roswell Park Memorial Institute 1640 medium (Biochrom). SK-N-BE(2) (neuroblastoma) cells were grown in DMEM/Ham\u2019s F-12 (1:1) and OVCAR-8 (ovarian cancer) cells were cultured in Iscove\u2019s modified Dulbecco\u2019s medium (Biochrom GmbH). All were supplemented with 10% (v/v) fetal bovine serum (Biochrom GmbH). Cell lines were tested internally for mycoplasma contamination. Cells were lysed in 0.8% IGEPAL (octylphenoxypolyethoxyethanol), 50 mM Tris-HCl pH 7.5, 5% glycerol, 1.5 mM MgCl <sub> 2 </sub> , 150 mM NaCl, 1 mM NA <sub> 3 </sub> VO <sub> 4 </sub> , 25 mM NaF, 1 mM dithiothreitol (DTT) and supplemented with protease inhibitors (SigmaFast, Sigma) and phosphatase inhibitors (PI-III; in house, composition resembling phosphatase inhibitor cocktail 1, 2 and 3 from Sigma-Aldrich). Protein concentration was determined by Bradford assay and aliquots were stored at \u221280 \u00b0C. </p> </section> <section id=\"Sec12\"> <h3 class=\"pmc_sec_title\"> Kinase inhibitor profiling with Kinobeads (Kinobeads pulldowns) </h3> <p id=\"Par33\"> Kinobeads pulldown experiments were performed as described previously <sup> <a aria-describedby=\"CR13\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR13\"> 13 </a> , <a aria-describedby=\"CR14\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR14\"> 14 </a> , <a aria-describedby=\"CR17\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR17\"> 17 </a> </sup> with minor modification. Briefly, the cell lysate mixture used for inhibitor profiling was generated from COLO-205, K-562, MV-4-11, SK-N-BE(2) and OVCAR-8 lysates by mixing them in a 1:1:1:1:1 ratio. The protein concentration was adjusted to 5 mg ml <sup> \u22121 </sup> . Kinase inhibitors were spiked into 0.5 ml of cell lysate at final concentrations of 100 and 1,000 nM (or DMSO, 0.3, 1, 3, 10, 30, 100, 300 and 1,000 nM for full dose experiments). In addition, six DMSO control pulldowns and three lestaurtinib pulldown experiments as control were distributed over a 96-well plate. Lysates were incubated for 45 min at 4 \u00b0C. Subsequently, lysates were incubated with Kinobeads \u03b5 (17.5 \u00b5l of settled beads) for 30 min at 4 \u00b0C. To assess the degree of protein depletion from the lysates by Kinobeads, the flow through of the DMSO control was recovered for a pulldown of pulldown experiment where the lysate was incubated a second time with fresh Kinobeads. Beads were washed in three steps with buffer containing 0.4%, 0.2% and no IGEPAL. Bound proteins were reduced with 50 mM DTT in 8 M Urea, 40 mM Tris-HCl pH 7.4 for 30 min at room temperature. After alkylation with 55 mM chloroacetamide, the urea concentration was reduced to 1\u20132 M and proteins were digested with trypsin. Acidified peptides were desalted and concentrated using SepPak tC18 \u00b5Eluation plates (Waters). Samples were frozen, dried by vacuum centrifugation and stored at \u221220 \u00b0C. </p> </section> <section id=\"Sec13\"> <h3 class=\"pmc_sec_title\"> LC\u2013MS/MS of Kinobeads pulldowns </h3> <p id=\"Par34\"> Nano liquid chromatography\u2013electrospray ionization with mass spectrometry (LC\u2013ESI\u2013MS) measurements of two-dose and full dose Kinobeads pulldown samples were performed using a Dionex Ultimate3000 nano high-performance liquid chromatography (HPLC) coupled online to an Orbitrap HF (Thermo Fisher Scientific) mass spectrometer. Peptides were delivered to a trap column (100 \u00b5m \u00d7 2 cm, packed in house with Reprosil-Pur C18-GOLD, 5 \u00b5m resin, Dr. Maisch) and washed for 10 min with 0.1% formic acid at a flow rate of 5 \u00b5l min <sup> \u22121 </sup> . Peptide separation was performed on an analytical column (75 \u00b5m ID \u00d7 40 cm packed in house with Reprosil-Pur C18, 3 \u00b5m resin, Dr. Maisch) at a flow rate of 300 nl min <sup> \u22121 </sup> using a 52 min gradient ranging from 5 to 33% solvent B (0.1% formic acid, 5% DMSO in acetonitrile (ACN)) in solvent A (0.1% formic acid in 5% DMSO). The Orbitrap HF was operated in data-dependent acquisition and positive ionization mode. MS1 spectra were acquired in the Orbitrap over a mass-to-charge ( <em> m </em> / <em> z </em> ) range of 360\u20131,300 <em> m </em> / <em> z </em> at a resolution of 120,000 (60,000 resolution for full dose Kinobeads pulldown samples) using an automatic gain control (AGC) target value of 3 \u00d7 10 <sup> 6 </sup> charges or a maximum injection time of 10 ms. Up to five (12 for eight dose pulldowns) peptide precursors were selected for fragmentation by higher energy collision-induced dissociation (HCD) using 25% normalized collision energy (NCE), an isolation width of 1.7 <em> m </em> / <em> z </em> , a maximum injection time of 22 ms (75 ms for eight dose pulldowns) and an AGC values of 1 \u00d7 10 <sup> 5 </sup> charges (2 \u00d7 10 <sup> 5 </sup> for full dose pulldowns). Resulted fragment ions were recorded in the Orbitrap with a resolution of 15 K. A previous experimentally obtained inclusion list containing approximately 3,700 kinase peptide <em> m </em> / <em> z </em> and their corresponding retention time values was enabled. Dynamic exclusion was set to 30 s. </p> </section> <section id=\"Sec14\"> <h3 class=\"pmc_sec_title\"> Peptide and protein identification and quantification of Kinobeads pulldowns </h3> <p id=\"Par35\"> Raw data files were searched with MaxQuant software (v.1.6.0.1) using standard settings unless otherwise described <sup> <a aria-describedby=\"CR18\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR18\"> 18 </a> </sup> . Tandem mass spectra were searched against all canonical protein sequences as annotated in the UniProt reference database (human proteins only, 20,230 entries, downloaded v.06.07.2017). Carbamidomethylated cysteine was set as fixed modification. Variable modifications included phosphorylation of serine, threonine or tyrosine, oxidation of methionine and N-terminal protein acetylation. Trypsin/P was specified as proteolytic enzyme with up to two missed cleavage sites. Label-free quantification and match between runs were enabled. Results were filtered for 1% peptide and protein false discovery rate (FDR) using a target-decoy approach using reversed protein sequences. </p> </section> <section id=\"Sec15\"> <h3 class=\"pmc_sec_title\"> Data analysis of Kinobeads pulldowns </h3> <p id=\"Par36\"> Each kinase inhibitor was processed together with all DMSO controls of the same plate. Additionally, each search was supplemented with five high quality DMSO controls for consistent peptide identification and protein grouping. The resultant file (proteinGroups.txt) was used for subsequent filtering, normalization, data visualization and target annotation that was automatically performed by a data processing pipeline built in house that used R (including the \u2018drc\u2019 and \u2018heatmap\u2019 packages). First, reverse hits, potential contaminants and not quantified proteins in the DMSO control samples were discarded. Protein raw and label-free quantification intensities were normalized to the median DMSO control intensity to obtain relative residual binding intensities for each protein group at every inhibitor concentration and standard deviations of the DMSO control intensity were calculated. IC <sub> 50 </sub> values were estimated based on the following equation </p> <table class=\"disp-formula p\" id=\"Equa\"> <tbody> <tr> <td class=\"formula\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"18\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </td> </tr> </tbody> </table> <p> where [ <em> I </em> ] is the inhibitor concentration that was used for IC <sub> 50 </sub> calculation and \u2018inhibition\u2019 the relative residual binding intensity. The formula was applied to the inhibitor concentration that showed residual binding close to 0.5. Estimated <span id=\"IEq19\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"19\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> values were then calculated by multiplying the estimated IC <sub> 50 </sub> values with a protein-dependent correction factor that was limited to a maximum value of one. The correction factor accounts for the depletion of a target protein from the lysate by Kinobeads. The depletion can be measured by the ratio of the amount of protein captured in two consecutive pulldowns of the same DMSO control lysate <sup> <a aria-describedby=\"CR57\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR57\"> 57 </a> </sup> . In this study, correction factors were determined in separate experiments using the same lysate mixture and the same bead batch. Correction factors were set to the median of all correction factors. Targets of kinase inhibitors were annotated using the previously published random forest classifier <sup> <a aria-describedby=\"CR19\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR19\"> 19 </a> </sup> . A training data set was annotated manually. Hereby, a protein was considered as target if the relative residual binding intensity was reduced by at least 30% at the highest compound concentration and if the standard deviation of the DMSO intensity was substantially lower than the overall reduction of the median relative intensity. Additionally, the number of unique peptides and MS/MS spectra were included as target selection criteria. Protein intensity in DMSO controls was also taken into account. Targets were considered as direct Kinobeads binders if annotated in Uniprot.org as protein kinase, lipid kinase, nucleotide binder, helicase, ATPase and GTPase as well as FAD and heme containing proteins. Most other target proteins were interaction partners and/or adaptor proteins of kinases, and were termed indirect Kinobeads binders. Binding affinities were reported as <span id=\"IEq20\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"20\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> values, which is the negative logarithm of <span id=\"IEq21\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"21\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> in mol l <sup> \u22121 </sup> . </p> <p id=\"Par37\"> For the target classifier, the targets of a limited number of compounds were annotated manually as described above and used as training set for the random forest model. The trained classifier assigns a target probability score to each quantified proteins in the data set ranging from 0 to 100%. Proteins with a target probability higher than 93.5% were annotated as target of the compound of interest and proteins below the threshold were annotated as no targets. The cutoff was used to reach the minimum overall number of false positive and false negative hits. </p> <p id=\"Par38\"> Full dose Kinobeads pulldowns were analyzed as reported previously <sup> <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> , <a aria-describedby=\"CR14\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR14\"> 14 </a> </sup> . </p> </section> <section id=\"Sec16\"> <h3 class=\"pmc_sec_title\"> CATDS score </h3> <p id=\"Par39\"> The CATDS is a measure of the target engagement of a specific protein at a certain drug concentration relative to the target engagement of all targets at that drug concentration. It was calculated as reported previously <sup> <a aria-describedby=\"CR3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR3\"> 3 </a> </sup> and as shown in the following equation </p> <table class=\"disp-formula p\" id=\"Equb\"> <tbody> <tr> <td class=\"formula\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"22\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </td> </tr> </tbody> </table> <p id=\"Par40\"> To determine the target engagement of a protein at any concentration, a slope of one was assumed and the top was set to one and the bottom was set to zero to generate a dose\u2013response curve based on the two-dose data. For curve fitting a four-parameter log-logistic regression model was used. </p> <table class=\"disp-formula p\" id=\"Equc\"> <tbody> <tr> <td class=\"formula\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"23\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </td> </tr> </tbody> </table> <p> where <em> c </em> is the compound concentration and the four free parameters are the plateau of the fit <em> b </em> (bottom), the maximal residual binding <em> t </em> (top) and the hill slope <em> s </em> of the curve at the infection point <em> I </em> (half-maximum effective concentration). The CATDS <sub> target </sub> was determined at the respective <span id=\"IEq22\" xmlns:mml=\"http://www.w3.org/1998/Math/MathML\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"24\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </span> concentration of the targeted protein for each inhibitor. </p> </section> <section id=\"Sec17\"> <h3 class=\"pmc_sec_title\"> Kinase activity assay </h3> <p id=\"Par41\"> Kinase activity assays were performed by ProQinase. Dose-dependent activity inhibition of CDK1/cyclinB, CK2alpha1 and CK2alpha2 were measured using a FlashPlateTM-based radiometric assay at <em> K </em> <sub> M </sub> (ATP) of the respective kinase. </p> </section> <section id=\"Sec18\"> <h3 class=\"pmc_sec_title\"> Cytokine secretion assay and phospho-SYK readout in response to SYK inhibitors </h3> <p id=\"Par42\"> Primary BMDCs were obtained from 9-week-old C57BL/6 mice that were maintained under standard specific pathogen-free conditions. BMDCs were differentiated for 7 days in Roswell Park Memorial Institute medium (Gibco) and granulocyte-macrophage colony-stimulating factor. On day seven, BMDCs were seeded in 96-well plates at 10 <sup> 5 </sup> cells per well in 100 \u00b5l of culture medium followed by incubation for 4 h at 37 \u00b0C. Subsequently, cells were incubated with SYK inhibitors for 30 min followed by stimulation with Zymosan (final concentration of 50 \u00b5g ml <sup> \u22121 </sup> ; Invivogen) and dispersed in culture medium for 24 h. Western blotting was performed using 15 \u03bcg of cell lysate and the following antibodies phospho-SYK-Tyr525/526 (1:1,000; Cell Signaling, catalog no. 2710), total SYK (1:1,000; Cell Signaling, catalog no. 2712) and b-actin (1:1,000; Proteintech, catalog no. 66009-1). For cytokine secretion quantification, cell culture medium was collected and concentrations of IL-10 in the supernatant were determined using mouse enzyme-linked immunosorbent assay kits (IL-10: Invitrogen) according to the manufacturer\u2019s protocol. Experiments were performed in biological triplicates. </p> </section> <section id=\"Sec19\"> <h3 class=\"pmc_sec_title\"> X-ray crystallography </h3> <p id=\"Par43\"> Expression and purification of CK2\u03b1 was done as described before <sup> <a aria-describedby=\"CR37\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR37\"> 37 </a> </sup> . Crystallization, soaking of ligands and structure determination was done as described previously. X-ray diffraction data were collected at the Diamond Light Source on the i24 and iO4 beamline and data from automated data processing with autoProc were used for the structure determination. All coordinated have been deposited to the PDB under accession numbers <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWE/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWE </a> , <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7A4Q/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7A4Q </a> and <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWG/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWG </a> . Data collection and refinement statistics are shown in Supplementary Table <a class=\"usa-link\" href=\"#MOESM5\"> 4 </a> . </p> </section> <section id=\"Sec20\"> <h3 class=\"pmc_sec_title\"> NanoBRET assay </h3> <p id=\"Par44\"> The NanoBRET assay was performed as described previously <sup> <a aria-describedby=\"CR28\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR28\"> 28 </a> , <a aria-describedby=\"CR58\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR58\"> 58 </a> </sup> . In brief, full-length PKN3, CSNK2A1 or CSNK2A2 ORF (PKN3 vector was a kind gift of Promega, Vectors for CSNK1A1 and CSNK1A2: NV2981, NV1191) cloned in frame with a C-terminal NanoLuc-fusion, respectively, were transfected into HEK293T cells using FuGENE HD (Promega, E2312) and proteins were allowed to express for 20 h. Serially diluted inhibitor and NanoBRET Kinase Tracer K5 (Promega, N2530) at 500 nM (PKN3) or NanoBRET Kinase Tracer K10 (Promega, N2840) at 500 nM (CSNK1A1 and CSNK1A2) were pipetted into 384-well plates using an Echo acoustic dispenser (Labcyte). The PKN3, CSNK2A1 or CSNK2A2 transfected cells were added at a density of 2 \u00d7 10 <sup> 5 </sup> cells per ml after trypsinization and resuspending in Opti-MEM without phenol red (Life Technologies). The system was allowed to equilibrate for 2 h at 37 \u00b0C and 5% CO <sub> 2 </sub> before BRET measurements. BRET signaling was measured by adding NanoBRET NanoGlo Substrate and Extracellular NanoLuc Inhibitor (Promega) according to the manufacturer\u2019s protocol. Filtered luminescence was measured on a PHERAstar plate reader (BMG Labtech) equipped with a luminescence filter pair (450 nm BP filter (donor) and 610 LP filter (acceptor)). Competitive displacement data were then graphed using GraphPad Prism software (v.5.01) using a three-parameter curve fit with the following equation </p> <table class=\"disp-formula p\" id=\"Equd\"> <tbody> <tr> <td class=\"formula\"> <mjx-container class=\"CtxtMenu_Attached_0\" ctxtmenu_counter=\"25\" ctxtmenu_oldtabindex=\"0\" tabindex=\"0\"> <mjx-lazy> </mjx-lazy> </mjx-container> </td> </tr> </tbody> </table> <p id=\"Par45\"> Experiments were performed with at least two biological and two technical replicates. </p> </section> <section id=\"Sec21\"> <h3 class=\"pmc_sec_title\"> PKN3 siRNA knockdown </h3> <p id=\"Par46\"> RKO cells were cultured in Iscove\u2019s modified Dulbecco\u2019s medium (Biochrom) supplemented with 10% (v/v) fetal bovine serum. Knockdown of PKN3 in RKO cells was performed by siRNA (siPOOL2 targeting human PKN3, NCBI gene ID 29941; siPOOLs Biotch) according to the instructions from the manufacturer. Briefly, PKN3 siRNA was diluted with Opti-MEM to a concentration of 0.05 \u03bcM. siRNA dilution was then mixed in a 1:1 ratio with Lipofectamine RNAiMAX (diluted by a factor 100 in Opti-MEM; Thermo Fisher Scientific) by vortexing and incubated for 5 min at room temperature. The transfection mixture was transferred to the bottom of a fresh 10 cm cell culture plate and RKO cells were added in a density of 1 \u00d7 10 <sup> 6 </sup> cells per ml. Knockdown was controlled by parallel reaction monitoring assay after 48 h of incubation. Therefore, cells were washed twice with phosphate-buffered saline and lysed by scraping in the presence of 100 \u00b5l of lysis buffer (0.8% IGEPAL, 50 mM Tris-HCl pH 7.5, 5% glycerol, 1.5 mM MgCl <sub> 2 </sub> , 150 mM NaCl, 1 mM NA <sub> 3 </sub> VO <sub> 4 </sub> , 25 mM NaF, 1 mM DTT, protease inhibitors (SigmaFast, Sigma) and phosphatase inhibitors). Lysates were centrifuged and proteins were alkylated with chloroacetamide (55 mM) and run into a 4\u201312% NuPAGE gel (Invitrogen, approximately 1 cm). In-gel digestion was performed according to standard procedures. </p> <p id=\"Par47\"> Based on previous Kinobeads LC with tandem mass spectrometry (LC\u2013MS/MS) runs various PKN3 peptides were selected to generate an inclusion list with 10 min monitoring windows. In addition, Prosit was used to generate a spectral library. Nanoflow LC\u2013ESI\u2013MS/MS measurements were performed with a DionexUltimate 3000UHPLC+ system coupled to a Q Exactive HF mass spectrometer (Thermo Fisher Scientific). After reconstitution in 0.1% FA, peptides were delivered to a trap column (75 mm \u00d7 2 cm, packed in house with 5 mmC18 resin; Reprosil-Pur AQ, Dr. Maisch) and washed using 0.1% formic acid at a flow rate of 5 ml min for 10 min. Subsequently, peptides were transferred to an analytical column (75 mm \u00d7 45 cm, packed in house with 3 mm C18 resin; Reprosil Gold, Dr. Maisch) applying a flow rate of 300 nl min <sup> \u22121 </sup> and separated using a 30 min linear gradient from 5 to 35% LC solvent B (0.1% FA, 5% DMSO in ACN) in LC solvent A (0.1% FA in 5% DMSO). The mass spectrometer was operated in positive ionization mode. Full scan MS1 spectra were recorded in the Orbitrap mass analyzer from 150 to 2,000 <em> m </em> / <em> z </em> at a resolution of 15,000 (at <em> m </em> / <em> z </em> 200) using an AGC target value of 3 \u00d7 10 <sup> 6 </sup> and a maximum injection time of 100 ms. For targeted MS2 scans, the scheduled precursors were isolated (isolation window 0.7 <em> m </em> / <em> z </em> ) and fragmented via HCD using a NCE of 25%. MS2 spectra were recorded in the Orbitrap mass analyzer at a resolution of 15,000 using an AGC target value of 2 \u00d7 10 <sup> 5 </sup> and a maximum injection time of 100 ms. </p> <p id=\"Par48\"> The generated .raw files were imported into Skyline for data filtering and analysis. Confident peptide identification was carried out based on matching to the predicted library and the dotp. Peaks were integrated using the automatic peak finding function followed by the manual curation of all peak boundaries and transitions. The summed area under the fragment ion traces for every transition was exported. All fragment ion traces were summed up for one peptide and relative intensities to the control samples were calculated. To determine the knockdown efficiency, relative intensities of six peptides were taken into account. A complete knockdown was observed after 48 h and a final siRNA concentration of 1 nM. </p> </section> <section id=\"Sec22\"> <h3 class=\"pmc_sec_title\"> Drug and siRNA-perturbed phosphoproteome analysis </h3> <p id=\"Par49\"> For global phosphoproteomic analysis of PKN3 inhibitors, RKO cells were treated with 1 \u00b5M GSK949675A, THZ1, GSK902056A, SB-476429A or DMSO for 1 h in four biological replicates or PKN3 were knocked down as described. After treatment, cells were washed twice with PBS and lyzed by adding 300 \u00b5l of lysis buffer (40 mM Tris-HCl pH 7.6, 8 M Urea, EDTA-free protease inhibitor complete mini and phosphatase inhibitor cocktail). Lysates were sonicated (ten cycles, 30 s on, 30 s pause, at 4 \u00b0C) and subsequently cleared by centrifugation for 20 min at 21,000 <em> g </em> at 4 \u00b0C. Protein concentration was determined by Bradford assay and 300 \u00b5g protein per condition was digested. After reduction with 10 mM DTT and alkylation of cysteine residues with 50 mM chloroacetamide, the Urea concentration was reduced to 1.5 M by adding six volumes of 40 mM Tris/HCl pH 7.6. Trypsin was added to a protease-to-protein ratio of 1:50 and digestion was performed over night at 37 \u00b0C and 700 r.p.m. on a thermoshaker. Samples were cooled down to room temperature and acidified to a pH &lt; 3 with 0.5% trifluoroacetic acid (TFA) and desalted using 50 mg SepPak columns (Waters; wash solvent 0.07% TFA in deionized water; elution solvent 0.07% TFA, 50% ACN). Subsequently, samples were frozen at \u221280 \u00b0C and dried by vacuum centrifugation. Peptide concentrations were determined by NanoDrop 2000 spectrophotometer and peptide amounts were adjusted. Dried peptides were labeled with TMT6plex as published previously <sup> <a aria-describedby=\"CR59\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR59\"> 59 </a> </sup> . One tandem mass tag (TMT) channel was used for each drug treatment (126 = SB-476429-A, 127 = GSK902056A, 128 = THZ1, 129 = GSK949675A, 130 = DMSO, 131 = PKN3 siRNA). Phosphopeptides were enriched using column based Fe-IMAC as described previously <sup> <a aria-describedby=\"CR60\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR60\"> 60 </a> </sup> . Subsequently, phosphopeptides were separated into six fractions using high pH reversed-phase stage tips as described before <sup> <a aria-describedby=\"CR61\" aria-expanded=\"false\" class=\"usa-link\" href=\"#CR61\"> 61 </a> </sup> . Samples were dried by vacuum centrifugation. </p> <p id=\"Par50\"> Nanoflow LC\u2013MS/MS measurement of TMT-labeled phosphopeptides was performed using a Dionex Ultimate3000 nano HPLC coupled online to an Orbitrap Fusion Lumos Tribride (Thermo Fisher Scientific) mass spectrometer. Peptides were delivered to a trap column (75 \u03bcm \u00d7 2 cm, packed in house with 5 \u03bcm C18 resin; Reprosil-Pur AQ, Dr. Maisch) and washed for 10 min with 0.1% FA at a flow rate of 5 \u03bcl min <sup> \u22121 </sup> . Subsequently, peptides were transferred to an analytical column (75 \u03bcm \u00d7 45 cm, packed in house with 3 \u03bcm C18 resin; Reprosil Gold, Dr. Maisch) at 300 nl min <sup> \u22121 </sup> and separated within a 90 min gradient ranging from 4 to 32% solvent B (0.1% FA, 5% DMSO in ACN) in solvent A (0.1% FA in 5% DMSO). MS1 spectra were recorded in the Orbitrap from 360 to 1,300 <em> m </em> / <em> z </em> at a resolution of 60,000 using an AGC target value of 4 \u00d7 10 <sup> 5 </sup> charges and a maximum injection time of 20 ms. MS2 spectra were recorded in the Orbitrap at 15,000 resolution after HCD fragmentation using 35% NCE, an AGC target value of 5 \u00d7 10 <sup> 4 </sup> , maximum injection time of 22 ms and an isolation width of 0.7 <em> m </em> / <em> z </em> . The first mass was fixed to 100 <em> m </em> / <em> z </em> . The number of MS2 spectra was limited by a top ten method. For TMT quantification, an additional MS3 spectrum was acquired in the Orbitrap over a scan range of 100\u20131,000 <em> m </em> / <em> z </em> at 15,000 resolution (AGC of 1 \u00d7 10 <sup> 5 </sup> , maximum injection time of 50 ms). For this, fragment ions were selected by multi-notch isolation in the Quadrupole, allowing a maximum of ten notches and subsequently fragmentation by HCD at 55% NCE. Dynamic exclusion was set to 90 s. </p> <p id=\"Par51\"> Peptide and protein identification and quantification were performed using MaxQuant with its built in search engine Andromeda. Tandem mass spectra were searched against all canonical protein sequences as annotated in the UniProt reference database (human proteins only, 20,230 entries, downloaded 6 July 2017). Carbamidomethylated cysteine was set as fixed modification. Variable modifications included phosphorylation of serine, threonine or tyrosine, oxidation of methionine and N-terminal protein acetylation. Trypsin/P was specified as proteolytic enzyme with up to two missed cleavage sites. TMT6plex reporter ions were specified for quantification and isotope impurities of TMT batches were specified in the configuration of modifications to allow automated correction of TMT intensities. Results were filtered for 1% peptide and protein FDR using a target-decoy approach using reversed protein sequences. </p> <p id=\"Par52\"> All four replicates were searched together. Decoy and potential contaminants were removed. Within one replicate the total sum of each TMT channel was calculated and normalized to the DMSO control (total sum normalization). Additionally, the average intensity for each phosphopeptide per replicate was normalized to the average intensity of the same phosphopeptide across all replicates (row wise normalization). The Perseus software (v.4.1.31.9) was used for Student\u2019s <em> t </em> -tests (two sided) using log-transformed TMT intensities. Statistical tests were corrected for multiple testing by an FDR of 1%. S0 was computed for each statistical test separately in R (function \u2018samr\u2019). Only phosphopeptides that were detected in at least three of four replicates were considered for analysis. GraphPad and excel were used for data visualization. </p> </section> <section id=\"Sec23\"> <h3 class=\"pmc_sec_title\"> Reporting summary </h3> <p id=\"Par53\"> Further information on research design is available in the <a class=\"usa-link\" href=\"#MOESM1\"> Nature Portfolio Reporting Summary </a> linked to this article. </p> </section> </section> <section id=\"Sec24\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"Sec24-anchor\"> </a> Online content </h2> <p id=\"Par54\"> Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41589-023-01459-3. </p> </section> <section id=\"sec25\"> <section id=\"Sec26\"> <h3 class=\"pmc_sec_title\"> Supplementary information </h3> <section class=\"sm xbox font-sm\" id=\"MOESM1\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM1_ESM.pdf\"> Reporting Summary </a> <sup> (1.6MB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"MOESM2\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM2_ESM.xlsx\"> <span> Supplementary Table 1 </span> </a> <sup> (665.1KB, xlsx) </sup> <p> Compound annotation. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"MOESM3\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM3_ESM.xlsx\"> <span> Supplementary Table 2 </span> </a> <sup> (701.7KB, xlsx) </sup> <p> Drug matrix of target affinity values. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"MOESM4\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM4_ESM.xlsx\"> <span> Supplementary Table 3 </span> </a> <sup> (2.1MB, xlsx) </sup> <p> Selectivities of tool compounds. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"MOESM5\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM5_ESM.xlsx\"> <span> Supplementary Table 4 </span> </a> <sup> (56KB, xlsx) </sup> <p> Results related to CK2 follow-up experiments. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"MOESM6\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM6_ESM.xlsx\"> <span> Supplementary Table 5 </span> </a> <sup> (13.4MB, xlsx) </sup> <p> Results related to PKN3 follow-up experiments. </p> </div> </div> </section> </section> <section id=\"Sec27\"> <h3 class=\"pmc_sec_title\"> Source data </h3> <section class=\"sm xbox font-sm\" id=\"MOESM7\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM7_ESM.pdf\"> <span> Source Data Fig. 3 </span> </a> <sup> (4.6MB, pdf) </sup> <p> Unprocessed western blots. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"MOESM8\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM8_ESM.pdf\"> <span> Source Data Extended Data Fig. 4 </span> </a> <sup> (10.3MB, pdf) </sup> <p> Unprocessed western blots. </p> </div> </div> </section> </section> </section> <section class=\"ack\" id=\"ack1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"ack1-anchor\"> </a> Acknowledgements </h2> <p> We thank J. Rechenberger, P. Prokofeva and S. Lechner for operating mass spectrometers. We also thank A. Hubauer, M. Kr\u00f6tz-Fahning and A. Klaus for technical assistance and S. Roffey for his assistance with CK2 inhibition experiments. The work was partly funded by the German Cancer Research Center (DKFZ) and the German Federal Ministry of Education and Research (BMBF, grant no. 031L0168). B.-T.B. and S.M. are grateful to the SGC, a registered charity (no. 1097737) that received funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute, Janssen, Merck KGaA, Pfizer and Takeda. This project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 875510. The Joint Undertaking receives support from the European Union\u2019s Horizon 2020 research and innovation program, EFPIA, Ontario Institute for Cancer Research, Royal Institution for the Advancement of Learning McGill University, Kungliga Tekniska Hoegskolan and Diamond Light Source Limited. Disclaimer: This communication reflects the views of the authors, and Joint Undertaking is not liable for any use that may be made of the information contained herein. B-T.B. also received support by the collaborative research center grant no. 1399 \u2018Mechanisms of drug sensitivity and resistance in small cell lung cancer\u2019. P.B. and M.H. are grateful for access to beamlines i24 and i03 at Diamond Light Source (proposal no. mx25402). This work was supported by research grants from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (Project-ID 360372040\u2013SFB 1335), and the European Research Council under the European Union\u2019s Horizon 2020 research and innovation program (grant agreement no. 834154) awarded to J.R. and the international doctoral program \u2018i-Target: Immunotargeting in Cancer\u2019, funded by the Elite Network of Bavaria to L.V. </p> </section> <section class=\"app\" id=\"App1\"> <section id=\"Sec25\"> <h3 class=\"pmc_sec_title\"> Extended data </h3> </section> </section> <section id=\"notes1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"notes1-anchor\"> </a> Author contributions </h2> <p> B.K. conceived and directed the project. M.R. and B.K. wrote the manuscript. M.R. profiled the drugs, performed the knockdown and phosphoproteomic experiment and measured the proteomic samples. P.B. and M.H. performed the CK2 crystal structure experiment. L.V. and J.R. performed the cytokine secretion assay. B.-T.B. and S.M. performed the NanoBRET binding assays. F.S. and M.W. developed the target classifier. P.S. and M.W. made the data available in ProtoemicsDB. L.G. and D.W.L. performed CK2 experiments. G.M. and S.W. provided expertise in data analysis and interpretation as well as planning follow-up experiments. </p> </section> <section id=\"notes2\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"notes2-anchor\"> </a> Peer review </h2> <section id=\"FPar3\"> <h3 class=\"pmc_sec_title\"> Peer review information </h3> <p id=\"Par57\"> <em> Nature Chemical Biology </em> thanks Matthew Robers and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. </p> </section> </section> <section id=\"notes3\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"notes3-anchor\"> </a> Data availability </h2> <p> The proteomic data, including the UniProt reference database, are available at the ProteomeXchange Consortium ( <a class=\"usa-link usa-link--external\" href=\"http://proteomecentral.proteomexchange.org\" rel=\"noopener noreferrer\" target=\"_blank\"> http://proteomecentral.proteomexchange.org </a> ) via the MassIVE partner repositories with the data set identifier <a class=\"usa-link usa-link--external\" href=\"https://massive.ucsd.edu/ProteoSAFe/QueryMSV?id=MSV000092248\" rel=\"noopener noreferrer\" target=\"_blank\"> MSV000092248 </a> , as well as at ProteomicsDB ( <a class=\"usa-link usa-link--external\" href=\"http://www.proteomicsdb.org\" rel=\"noopener noreferrer\" target=\"_blank\"> www.proteomicsdb.org </a> ). Crystal structure coordinates and structure factors have been deposited to PDB under accession numbers <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWE/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWE </a> , <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7A4Q/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7A4Q </a> and <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWG/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWG </a> . <a class=\"usa-link\" href=\"#Sec27\"> Source data </a> are provided with this paper. </p> </section> <section id=\"FPar4\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"FPar4-anchor\"> </a> Competing interests </h2> <p id=\"Par58\"> M.W. and B.K. are founders and shareholders of OmicScouts GmbH and MSAID GmbH. They have no operational role in either company. B.-T.B. is a cofounder and the CEO of CELLinib GmbH (Frankfurt am Main, Germany). The remaining authors declare no competing interests. </p> </section> <section class=\"fn-group\" id=\"fn-group1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"fn-group1-anchor\"> </a> Footnotes </h2> <div class=\"fn-group p font-secondary-light font-sm\"> <div class=\"fn p\" id=\"fn1\"> <p> <strong> Publisher\u2019s note </strong> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. </p> </div> </div> </section> <section id=\"sec29\"> <section id=\"FPar1\"> <h3 class=\"pmc_sec_title\"> Extended data </h3> <p id=\"Par55\"> is available for this paper at 10.1038/s41589-023-01459-3. </p> </section> <section id=\"FPar2\"> <h3 class=\"pmc_sec_title\"> Supplementary information </h3> <p id=\"Par56\"> The online version contains supplementary material available at 10.1038/s41589-023-01459-3. </p> </section> </section> <section class=\"ref-list\" id=\"Bib1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"Bib1-anchor\"> </a> References </h2> <section id=\"Bib1_sec2\"> <ul class=\"ref-list font-sm\"> <li id=\"CR1\"> <span class=\"label\"> 1. </span> <cite> Ayala-Aguilera CC, et al. Small molecule kinase inhibitor drugs (1995\u20132021): medical indication, pharmacology, and synthesis. J. Med. Chem. 2022;65:1047\u20131131. doi: 10.1021/acs.jmedchem.1c00963. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/acs.jmedchem.1c00963\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34624192/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Small%20molecule%20kinase%20inhibitor%20drugs%20(1995%E2%80%932021):%20medical%20indication,%20pharmacology,%20and%20synthesis&amp;author=CC%20Ayala-Aguilera&amp;volume=65&amp;publication_year=2022&amp;pages=1047-1131&amp;pmid=34624192&amp;doi=10.1021/acs.jmedchem.1c00963&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR2\"> <span class=\"label\"> 2. </span> <cite> Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem. 2010;53:1413\u20131437. doi: 10.1021/jm901132v. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/jm901132v\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20166671/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Selectively%20nonselective%20kinase%20inhibition:%20striking%20the%20right%20balance&amp;author=R%20Morphy&amp;volume=53&amp;publication_year=2010&amp;pages=1413-1437&amp;pmid=20166671&amp;doi=10.1021/jm901132v&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR3\"> <span class=\"label\"> 3. </span> <cite> Klaeger S, et al. The target landscape of clinical kinase drugs. Science. 2017;358:eaan4368. doi: 10.1126/science.aan4368. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1126/science.aan4368\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6542668/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29191878/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Science&amp;title=The%20target%20landscape%20of%20clinical%20kinase%20drugs&amp;author=S%20Klaeger&amp;volume=358&amp;publication_year=2017&amp;pages=eaan4368&amp;pmid=29191878&amp;doi=10.1126/science.aan4368&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR4\"> <span class=\"label\"> 4. </span> <cite> M\u00fcller S, et al. Donated chemical probes for open science. eLife. 2018;7:e34311. doi: 10.7554/eLife.34311. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.7554/eLife.34311\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5910019/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29676732/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=eLife&amp;title=Donated%20chemical%20probes%20for%20open%20science&amp;author=S%20M%C3%BCller&amp;volume=7&amp;publication_year=2018&amp;pages=e34311&amp;pmid=29676732&amp;doi=10.7554/eLife.34311&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR5\"> <span class=\"label\"> 5. </span> <cite> Antolin, A. A., Workman, P. &amp; Al-Lazikani, B. Public resources for chemical probes: the journey so far and the road ahead. <em> Future Med. Chem. </em> 10.4155/fmc-2019-0231 (2019). </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.4155/fmc-2019-0231\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31778323/\"> PubMed </a> ] </li> <li id=\"CR6\"> <span class=\"label\"> 6. </span> <cite> Workman P, Collins I. Probing the probes: fitness factors for small molecule tools. Chem. Biol. 2010;17:561\u2013577. doi: 10.1016/j.chembiol.2010.05.013. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.chembiol.2010.05.013\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2905514/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20609406/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Chem.%20Biol.&amp;title=Probing%20the%20probes:%20fitness%20factors%20for%20small%20molecule%20tools&amp;author=P%20Workman&amp;author=I%20Collins&amp;volume=17&amp;publication_year=2010&amp;pages=561-577&amp;pmid=20609406&amp;doi=10.1016/j.chembiol.2010.05.013&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR7\"> <span class=\"label\"> 7. </span> <cite> Donovan KA, et al. Mapping the degradable kinome provides a resource for expedited degrader development. Cell. 2020;183:1714\u20131731.e1710. doi: 10.1016/j.cell.2020.10.038. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.cell.2020.10.038\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC10294644/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33275901/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Mapping%20the%20degradable%20kinome%20provides%20a%20resource%20for%20expedited%20degrader%20development&amp;author=KA%20Donovan&amp;volume=183&amp;publication_year=2020&amp;pages=1714-1731.e1710&amp;pmid=33275901&amp;doi=10.1016/j.cell.2020.10.038&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR8\"> <span class=\"label\"> 8. </span> <cite> Edwards AM, et al. Too many roads not taken. Nature. 2011;470:163\u2013165. doi: 10.1038/470163a. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/470163a\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21307913/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Too%20many%20roads%20not%20taken&amp;author=AM%20Edwards&amp;volume=470&amp;publication_year=2011&amp;pages=163-165&amp;pmid=21307913&amp;doi=10.1038/470163a&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR9\"> <span class=\"label\"> 9. </span> <cite> M\u00fcller S, et al. Target 2035\u2014update on the quest for a probe for every protein. RSC Med. Chem. 2022;13:13\u201321. doi: 10.1039/d1md00228g. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1039/d1md00228g\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8792830/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/35211674/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=RSC%20Med.%20Chem.&amp;title=Target%202035%E2%80%94update%20on%20the%20quest%20for%20a%20probe%20for%20every%20protein&amp;author=S%20M%C3%BCller&amp;volume=13&amp;publication_year=2022&amp;pages=13-21&amp;pmid=35211674&amp;doi=10.1039/d1md00228g&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR10\"> <span class=\"label\"> 10. </span> <cite> Elkins JM, et al. Comprehensive characterization of the Published Kinase Inhibitor Set. Nat. Biotechnol. 2016;34:95\u2013103. doi: 10.1038/nbt.3374. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nbt.3374\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26501955/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat.%20Biotechnol.&amp;title=Comprehensive%20characterization%20of%20the%20Published%20Kinase%20Inhibitor%20Set&amp;author=JM%20Elkins&amp;volume=34&amp;publication_year=2016&amp;pages=95-103&amp;pmid=26501955&amp;doi=10.1038/nbt.3374&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR11\"> <span class=\"label\"> 11. </span> <cite> Drewry DH, et al. Progress towards a public chemogenomic set for protein kinases and a call for contributions. PLoS ONE. 2017;12:e0181585. doi: 10.1371/journal.pone.0181585. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1371/journal.pone.0181585\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5540273/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28767711/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Progress%20towards%20a%20public%20chemogenomic%20set%20for%20protein%20kinases%20and%20a%20call%20for%20contributions&amp;author=DH%20Drewry&amp;volume=12&amp;publication_year=2017&amp;pages=e0181585&amp;pmid=28767711&amp;doi=10.1371/journal.pone.0181585&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR12\"> <span class=\"label\"> 12. </span> <cite> Wells CI, et al. The Kinase Chemogenomic Set (KCGS): an open science resource for kinase vulnerability identification. Int. J. Mol. Sci. 2021;22:566. doi: 10.3390/ijms22020566. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3390/ijms22020566\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7826789/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33429995/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=The%20Kinase%20Chemogenomic%20Set%20(KCGS):%20an%20open%20science%20resource%20for%20kinase%20vulnerability%20identification&amp;author=CI%20Wells&amp;volume=22&amp;publication_year=2021&amp;pages=566&amp;pmid=33429995&amp;doi=10.3390/ijms22020566&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR13\"> <span class=\"label\"> 13. </span> <cite> M\u00e9dard G, et al. Optimized chemical proteomics assay for kinase inhibitor profiling. J. Proteome Res. 2015;14:1574\u20131586. doi: 10.1021/pr5012608. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/pr5012608\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25660469/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Proteome%20Res.&amp;title=Optimized%20chemical%20proteomics%20assay%20for%20kinase%20inhibitor%20profiling&amp;author=G%20M%C3%A9dard&amp;volume=14&amp;publication_year=2015&amp;pages=1574-1586&amp;pmid=25660469&amp;doi=10.1021/pr5012608&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR14\"> <span class=\"label\"> 14. </span> <cite> Reinecke M, et al. Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors. ACS Chem. Biol. 2019;14:655\u2013664. doi: 10.1021/acschembio.8b01020. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/acschembio.8b01020\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/30901187/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=ACS%20Chem.%20Biol.&amp;title=Chemoproteomic%20selectivity%20profiling%20of%20PIKK%20and%20PI3K%20kinase%20inhibitors&amp;author=M%20Reinecke&amp;volume=14&amp;publication_year=2019&amp;pages=655-664&amp;pmid=30901187&amp;doi=10.1021/acschembio.8b01020&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR15\"> <span class=\"label\"> 15. </span> <cite> Duncan JamesS, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012;149:307\u2013321. doi: 10.1016/j.cell.2012.02.053. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.cell.2012.02.053\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3328787/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22500798/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Dynamic%20reprogramming%20of%20the%20kinome%20in%20response%20to%20targeted%20MEK%20inhibition%20in%20triple-negative%20breast%20cancer&amp;author=JamesS%20Duncan&amp;volume=149&amp;publication_year=2012&amp;pages=307-321&amp;pmid=22500798&amp;doi=10.1016/j.cell.2012.02.053&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR16\"> <span class=\"label\"> 16. </span> <cite> Patricelli MatthewP, et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 2011;18:699\u2013710. doi: 10.1016/j.chembiol.2011.04.011. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.chembiol.2011.04.011\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3142620/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21700206/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Chem.%20Biol.&amp;title=In%20situ%20kinase%20profiling%20reveals%20functionally%20relevant%20properties%20of%20native%20kinases&amp;author=MatthewP%20Patricelli&amp;volume=18&amp;publication_year=2011&amp;pages=699-710&amp;pmid=21700206&amp;doi=10.1016/j.chembiol.2011.04.011&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR17\"> <span class=\"label\"> 17. </span> <cite> Reinecke, M., Heinzlmeir, S., Wilhelm, M., M\u00e9dard, G. &amp; Kuster, B. in <em> Target Discovery and Validation </em> (ed. Plowright, A. T.) 97\u2013130 (2020). </cite> </li> <li id=\"CR18\"> <span class=\"label\"> 18. </span> <cite> Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc. 2016;11:2301\u20132319. doi: 10.1038/nprot.2016.136. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nprot.2016.136\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27809316/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat.%20Protoc.&amp;title=The%20MaxQuant%20computational%20platform%20for%20mass%20spectrometry-based%20shotgun%20proteomics&amp;author=S%20Tyanova&amp;author=T%20Temu&amp;author=J%20Cox&amp;volume=11&amp;publication_year=2016&amp;pages=2301-2319&amp;pmid=27809316&amp;doi=10.1038/nprot.2016.136&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR19\"> <span class=\"label\"> 19. </span> <cite> Seefried F, et al. CiRCus: a framework to enable classification of complex high-throughput experiments. J. Proteome Res. 2019;18:1486\u20131493. doi: 10.1021/acs.jproteome.8b00724. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/acs.jproteome.8b00724\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/30799618/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Proteome%20Res.&amp;title=CiRCus:%20a%20framework%20to%20enable%20classification%20of%20complex%20high-throughput%20experiments&amp;author=F%20Seefried&amp;volume=18&amp;publication_year=2019&amp;pages=1486-1493&amp;pmid=30799618&amp;doi=10.1021/acs.jproteome.8b00724&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR20\"> <span class=\"label\"> 20. </span> <cite> Rudolf AF, Skovgaard T, Knapp S, Jensen LJ, Berthelsen J. A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination. PLoS ONE. 2014;9:e98800. doi: 10.1371/journal.pone.0098800. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1371/journal.pone.0098800\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4051630/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24915177/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=A%20comparison%20of%20protein%20kinases%20inhibitor%20screening%20methods%20using%20both%20enzymatic%20activity%20and%20binding%20affinity%20determination&amp;author=AF%20Rudolf&amp;author=T%20Skovgaard&amp;author=S%20Knapp&amp;author=LJ%20Jensen&amp;author=J%20Berthelsen&amp;volume=9&amp;publication_year=2014&amp;pages=e98800&amp;pmid=24915177&amp;doi=10.1371/journal.pone.0098800&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR21\"> <span class=\"label\"> 21. </span> <cite> Bantscheff M, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007;25:1035\u20131044. doi: 10.1038/nbt1328. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nbt1328\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/17721511/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat.%20Biotechnol.&amp;title=Quantitative%20chemical%20proteomics%20reveals%20mechanisms%20of%20action%20of%20clinical%20ABL%20kinase%20inhibitors&amp;author=M%20Bantscheff&amp;volume=25&amp;publication_year=2007&amp;pages=1035-1044&amp;pmid=17721511&amp;doi=10.1038/nbt1328&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR22\"> <span class=\"label\"> 22. </span> <cite> Klaeger S, et al. Chemical proteomics reveals ferrochelatase as a common off-target of kinase inhibitors. ACS Chem. Biol. 2016;11:1245\u20131254. doi: 10.1021/acschembio.5b01063. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/acschembio.5b01063\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26863403/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=ACS%20Chem.%20Biol.&amp;title=Chemical%20proteomics%20reveals%20ferrochelatase%20as%20a%20common%20off-target%20of%20kinase%20inhibitors&amp;author=S%20Klaeger&amp;volume=11&amp;publication_year=2016&amp;pages=1245-1254&amp;pmid=26863403&amp;doi=10.1021/acschembio.5b01063&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR23\"> <span class=\"label\"> 23. </span> <cite> Heinzlmeir S, et al. Chemoproteomics-aided medicinal chemistry for the discovery of EPHA2 inhibitors. Chem. Med. Chem. 2017;12:999\u20131011. doi: 10.1002/cmdc.201700217. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1002/cmdc.201700217\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28544567/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Chem.%20Med.%20Chem.&amp;title=Chemoproteomics-aided%20medicinal%20chemistry%20for%20the%20discovery%20of%20EPHA2%20inhibitors&amp;author=S%20Heinzlmeir&amp;volume=12&amp;publication_year=2017&amp;pages=999-1011&amp;pmid=28544567&amp;doi=10.1002/cmdc.201700217&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR24\"> <span class=\"label\"> 24. </span> <cite> Lochhead PA, et al. Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nat. Commun. 2020;11:1383. doi: 10.1038/s41467-020-15031-3. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41467-020-15031-3\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7069993/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32170057/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Paradoxical%20activation%20of%20the%20protein%20kinase-transcription%20factor%20ERK5%20by%20ERK5%20kinase%20inhibitors&amp;author=PA%20Lochhead&amp;volume=11&amp;publication_year=2020&amp;pages=1383&amp;pmid=32170057&amp;doi=10.1038/s41467-020-15031-3&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR25\"> <span class=\"label\"> 25. </span> <cite> Arrowsmith CH, et al. The promise and peril of chemical probes. Nat. Chem. Biol. 2015;11:536\u2013541. doi: 10.1038/nchembio.1867. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nchembio.1867\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4706458/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26196764/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat.%20Chem.%20Biol.&amp;title=The%20promise%20and%20peril%20of%20chemical%20probes&amp;author=CH%20Arrowsmith&amp;volume=11&amp;publication_year=2015&amp;pages=536-541&amp;pmid=26196764&amp;doi=10.1038/nchembio.1867&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR26\"> <span class=\"label\"> 26. </span> <cite> Wells CI, et al. Quantifying CDK inhibitor selectivity in live cells. Nat. Commun. 2020;11:2743. doi: 10.1038/s41467-020-16559-0. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41467-020-16559-0\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7265341/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32488087/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Quantifying%20CDK%20inhibitor%20selectivity%20in%20live%20cells&amp;author=CI%20Wells&amp;volume=11&amp;publication_year=2020&amp;pages=2743&amp;pmid=32488087&amp;doi=10.1038/s41467-020-16559-0&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR27\"> <span class=\"label\"> 27. </span> <cite> Lebakken CS, Reichling LJ, Ellefson JM, Riddle SM. Detection of allosteric kinase inhibitors by displacement of active site probes. J. Biomol. Screen. 2012;17:813\u2013821. doi: 10.1177/1087057112439889. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1177/1087057112439889\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22453235/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Biomol.%20Screen.&amp;title=Detection%20of%20allosteric%20kinase%20inhibitors%20by%20displacement%20of%20active%20site%20probes&amp;author=CS%20Lebakken&amp;author=LJ%20Reichling&amp;author=JM%20Ellefson&amp;author=SM%20Riddle&amp;volume=17&amp;publication_year=2012&amp;pages=813-821&amp;pmid=22453235&amp;doi=10.1177/1087057112439889&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR28\"> <span class=\"label\"> 28. </span> <cite> Vasta JD, et al. Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement. Cell Chem. Biol. 2018;25:206\u2013214.e211. doi: 10.1016/j.chembiol.2017.10.010. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.chembiol.2017.10.010\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5814754/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29174542/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell%20Chem.%20Biol.&amp;title=Quantitative,%20wide-spectrum%20kinase%20profiling%20in%20live%20cells%20for%20assessing%20the%20effect%20of%20cellular%20ATP%20on%20target%20engagement&amp;author=JD%20Vasta&amp;volume=25&amp;publication_year=2018&amp;pages=206-214.e211&amp;pmid=29174542&amp;doi=10.1016/j.chembiol.2017.10.010&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR29\"> <span class=\"label\"> 29. </span> <cite> Matsuoka H, Obama H, Kelly ML, Matsui T, Nakamoto M. Biphasic functions of the kinase-defective Ephb6 receptor in cell adhesion and migration. J. Biol. Chem. 2005;280:29355\u201329363. doi: 10.1074/jbc.M500010200. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1074/jbc.M500010200\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/15955811/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Biol.%20Chem.&amp;title=Biphasic%20functions%20of%20the%20kinase-defective%20Ephb6%20receptor%20in%20cell%20adhesion%20and%20migration&amp;author=H%20Matsuoka&amp;author=H%20Obama&amp;author=ML%20Kelly&amp;author=T%20Matsui&amp;author=M%20Nakamoto&amp;volume=280&amp;publication_year=2005&amp;pages=29355-29363&amp;pmid=15955811&amp;doi=10.1074/jbc.M500010200&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR30\"> <span class=\"label\"> 30. </span> <cite> Byrne DP, Foulkes DM, Eyers PA. Pseudokinases: update on their functions and evaluation as new drug targets. Future Med. Chem. 2017;9:245\u2013265. doi: 10.4155/fmc-2016-0207. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.4155/fmc-2016-0207\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28097887/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Future%20Med.%20Chem.&amp;title=Pseudokinases:%20update%20on%20their%20functions%20and%20evaluation%20as%20new%20drug%20targets&amp;author=DP%20Byrne&amp;author=DM%20Foulkes&amp;author=PA%20Eyers&amp;volume=9&amp;publication_year=2017&amp;pages=245-265&amp;pmid=28097887&amp;doi=10.4155/fmc-2016-0207&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR31\"> <span class=\"label\"> 31. </span> <cite> Braegelmann C, et al. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. Exp. Dermatol. 2016;25:375\u2013379. doi: 10.1111/exd.12986. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1111/exd.12986\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26910509/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Exp.%20Dermatol.&amp;title=Spleen%20tyrosine%20kinase%20(SYK)%20is%20a%20potential%20target%20for%20the%20treatment%20of%20cutaneous%20lupus%20erythematosus%20patients&amp;author=C%20Braegelmann&amp;volume=25&amp;publication_year=2016&amp;pages=375-379&amp;pmid=26910509&amp;doi=10.1111/exd.12986&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR32\"> <span class=\"label\"> 32. </span> <cite> Masuda ES, Schmitz J. Syk inhibitors as treatment for allergic rhinitis. Pulm. Pharmacol. Ther. 2008;21:461\u2013467. doi: 10.1016/j.pupt.2007.06.002. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.pupt.2007.06.002\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/17669674/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Pulm.%20Pharmacol.%20Ther.&amp;title=Syk%20inhibitors%20as%20treatment%20for%20allergic%20rhinitis&amp;author=ES%20Masuda&amp;author=J%20Schmitz&amp;volume=21&amp;publication_year=2008&amp;pages=461-467&amp;pmid=17669674&amp;doi=10.1016/j.pupt.2007.06.002&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR33\"> <span class=\"label\"> 33. </span> <cite> Liu D, Mamorska-Dyga A. Syk inhibitors in clinical development for hematological malignancies. J. Hematol. Oncol. 2017;10:145. doi: 10.1186/s13045-017-0512-1. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1186/s13045-017-0512-1\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5534090/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28754125/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Hematol.%20Oncol.&amp;title=Syk%20inhibitors%20in%20clinical%20development%20for%20hematological%20malignancies&amp;author=D%20Liu&amp;author=A%20Mamorska-Dyga&amp;volume=10&amp;publication_year=2017&amp;pages=145&amp;pmid=28754125&amp;doi=10.1186/s13045-017-0512-1&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR34\"> <span class=\"label\"> 34. </span> <cite> Gross O, et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature. 2006;442:651\u2013656. doi: 10.1038/nature04926. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nature04926\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/16862125/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Card9%20controls%20a%20non-TLR%20signalling%20pathway%20for%20innate%20anti-fungal%20immunity&amp;author=O%20Gross&amp;volume=442&amp;publication_year=2006&amp;pages=651-656&amp;pmid=16862125&amp;doi=10.1038/nature04926&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR35\"> <span class=\"label\"> 35. </span> <cite> Zonta F, et al. Contribution of the CK2 catalytic isoforms \u03b1 and \u03b1\u2019 to the glycolytic phenotype of tumor cells. Cells. 2021;10:181. doi: 10.3390/cells10010181. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3390/cells10010181\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7831337/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33477590/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=Contribution%20of%20the%20CK2%20catalytic%20isoforms%20%CE%B1%20and%20%CE%B1%E2%80%99%20to%20the%20glycolytic%20phenotype%20of%20tumor%20cells&amp;author=F%20Zonta&amp;volume=10&amp;publication_year=2021&amp;pages=181&amp;pmid=33477590&amp;doi=10.3390/cells10010181&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR36\"> <span class=\"label\"> 36. </span> <cite> Trembley JH, et al. Emergence of protein kinase CK2 as a key target in cancer therapy. BioFactors. 2010;36:187\u2013195. doi: 10.1002/biof.96. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1002/biof.96\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2916697/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20533398/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=BioFactors&amp;title=Emergence%20of%20protein%20kinase%20CK2%20as%20a%20key%20target%20in%20cancer%20therapy&amp;author=JH%20Trembley&amp;volume=36&amp;publication_year=2010&amp;pages=187-195&amp;pmid=20533398&amp;doi=10.1002/biof.96&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR37\"> <span class=\"label\"> 37. </span> <cite> Brear P, et al. Specific inhibition of CK2\u03b1 from an anchor outside the active site. Chem. Sci. 2016;7:6839\u20136845. doi: 10.1039/c6sc02335e. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1039/c6sc02335e\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5355960/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28451126/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Chem.%20Sci.&amp;title=Specific%20inhibition%20of%20CK2%CE%B1%20from%20an%20anchor%20outside%20the%20active%20site&amp;author=P%20Brear&amp;volume=7&amp;publication_year=2016&amp;pages=6839-6845&amp;pmid=28451126&amp;doi=10.1039/c6sc02335e&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR38\"> <span class=\"label\"> 38. </span> <cite> Vassilev LT, et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl Acad. Sci. USA. 2006;103:10660\u201310665. doi: 10.1073/pnas.0600447103. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1073/pnas.0600447103\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC1502288/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/16818887/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;title=Selective%20small-molecule%20inhibitor%20reveals%20critical%20mitotic%20functions%20of%20human%20CDK1&amp;author=LT%20Vassilev&amp;volume=103&amp;publication_year=2006&amp;pages=10660-10665&amp;pmid=16818887&amp;doi=10.1073/pnas.0600447103&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR39\"> <span class=\"label\"> 39. </span> <cite> Chen S, et al. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. Bioorg. Med. Chem. Lett. 2007;17:2134\u20132138. doi: 10.1016/j.bmcl.2007.01.081. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.bmcl.2007.01.081\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/17303421/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Med.%20Chem.%20Lett.&amp;title=Synthesis%20and%20activity%20of%20quinolinyl-methylene-thiazolinones%20as%20potent%20and%20selective%20cyclin-dependent%20kinase%201%20inhibitors&amp;author=S%20Chen&amp;volume=17&amp;publication_year=2007&amp;pages=2134-2138&amp;pmid=17303421&amp;doi=10.1016/j.bmcl.2007.01.081&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR40\"> <span class=\"label\"> 40. </span> <cite> Knight JDR, Qian B, Baker D, Kothary R. Conservation, variability and the modeling of active protein kinases. PLoS ONE. 2007;2:e982. doi: 10.1371/journal.pone.0000982. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1371/journal.pone.0000982\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC1989141/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/17912359/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Conservation,%20variability%20and%20the%20modeling%20of%20active%20protein%20kinases&amp;author=JDR%20Knight&amp;author=B%20Qian&amp;author=D%20Baker&amp;author=R%20Kothary&amp;volume=2&amp;publication_year=2007&amp;pages=e982&amp;pmid=17912359&amp;doi=10.1371/journal.pone.0000982&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR41\"> <span class=\"label\"> 41. </span> <cite> Battistutta R, et al. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry. 2011;50:8478\u20138488. doi: 10.1021/bi2008382. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/bi2008382\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21870818/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Unprecedented%20selectivity%20and%20structural%20determinants%20of%20a%20new%20class%20of%20protein%20kinase%20CK2%20inhibitors%20in%20clinical%20trials%20for%20the%20treatment%20of%20cancer&amp;author=R%20Battistutta&amp;volume=50&amp;publication_year=2011&amp;pages=8478-8488&amp;pmid=21870818&amp;doi=10.1021/bi2008382&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR42\"> <span class=\"label\"> 42. </span> <cite> Bogusz J, et al. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors. Sci. Rep. 2017;7:13399. doi: 10.1038/s41598-017-13557-z. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41598-017-13557-z\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5645348/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29042609/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Sci.%20Rep.&amp;title=Structural%20analysis%20of%20PIM1%20kinase%20complexes%20with%20ATP-competitive%20inhibitors&amp;author=J%20Bogusz&amp;volume=7&amp;publication_year=2017&amp;pages=13399&amp;pmid=29042609&amp;doi=10.1038/s41598-017-13557-z&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR43\"> <span class=\"label\"> 43. </span> <cite> Lee JY, et al. Structural basis for the selective inhibition of Cdc2-like kinases by CX-4945. BioMed. Res. Int. 2019;2019:6125068. doi: 10.1155/2019/6125068. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1155/2019/6125068\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6720368/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31531359/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=BioMed.%20Res.%20Int.&amp;title=Structural%20basis%20for%20the%20selective%20inhibition%20of%20Cdc2-like%20kinases%20by%20CX-4945&amp;author=JY%20Lee&amp;volume=2019&amp;publication_year=2019&amp;pages=6125068&amp;pmid=31531359&amp;doi=10.1155/2019/6125068&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR44\"> <span class=\"label\"> 44. </span> <cite> Kim H, et al. Identification of a novel function of CX-4945 as a splicing regulator. PLoS ONE. 2014;9:e94978. doi: 10.1371/journal.pone.0094978. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1371/journal.pone.0094978\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3990583/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24743259/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Identification%20of%20a%20novel%20function%20of%20CX-4945%20as%20a%20splicing%20regulator&amp;author=H%20Kim&amp;volume=9&amp;publication_year=2014&amp;pages=e94978&amp;pmid=24743259&amp;doi=10.1371/journal.pone.0094978&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR45\"> <span class=\"label\"> 45. </span> <cite> Kaminskyy D, Kryshchyshyn A, Lesyk R. Recent developments with rhodanine as a scaffold for drug discovery. Expert Opin. Drug Discov. 2017;12:1233\u20131252. doi: 10.1080/17460441.2017.1388370. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1080/17460441.2017.1388370\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29019278/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Expert%20Opin.%20Drug%20Discov.&amp;title=Recent%20developments%20with%20rhodanine%20as%20a%20scaffold%20for%20drug%20discovery&amp;author=D%20Kaminskyy&amp;author=A%20Kryshchyshyn&amp;author=R%20Lesyk&amp;volume=12&amp;publication_year=2017&amp;pages=1233-1252&amp;pmid=29019278&amp;doi=10.1080/17460441.2017.1388370&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR46\"> <span class=\"label\"> 46. </span> <cite> Dibus M, Br\u00e1bek J, R\u00f6sel D. A screen for PKN3 substrates reveals an activating phosphorylation of ARHGAP18. Int. J. Mol. Sci. 2020;21:7769. doi: 10.3390/ijms21207769. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3390/ijms21207769\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7594087/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33092266/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Mol.%20Sci.&amp;title=A%20screen%20for%20PKN3%20substrates%20reveals%20an%20activating%20phosphorylation%20of%20ARHGAP18&amp;author=M%20Dibus&amp;author=J%20Br%C3%A1bek&amp;author=D%20R%C3%B6sel&amp;volume=21&amp;publication_year=2020&amp;pages=7769&amp;pmid=33092266&amp;doi=10.3390/ijms21207769&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR47\"> <span class=\"label\"> 47. </span> <cite> Leenders F, et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J. 2004;23:3303\u20133313. doi: 10.1038/sj.emboj.7600345. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/sj.emboj.7600345\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC514518/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/15282551/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=EMBO%20J.&amp;title=PKN3%20is%20required%20for%20malignant%20prostate%20cell%20growth%20downstream%20of%20activated%20PI%203-kinase&amp;author=F%20Leenders&amp;volume=23&amp;publication_year=2004&amp;pages=3303-3313&amp;pmid=15282551&amp;doi=10.1038/sj.emboj.7600345&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR48\"> <span class=\"label\"> 48. </span> <cite> Unsal-Kacmaz K, et al. The interaction of PKN3 with RhoC promotes malignant growth. Mol. Oncol. 2012;6:284\u2013298. doi: 10.1016/j.molonc.2011.12.001. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.molonc.2011.12.001\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5528337/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22217540/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mol.%20Oncol.&amp;title=The%20interaction%20of%20PKN3%20with%20RhoC%20promotes%20malignant%20growth&amp;author=K%20Unsal-Kacmaz&amp;volume=6&amp;publication_year=2012&amp;pages=284-298&amp;pmid=22217540&amp;doi=10.1016/j.molonc.2011.12.001&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR49\"> <span class=\"label\"> 49. </span> <cite> Schultheis B, et al. Safety, efficacy and pharcacokinetics of targeted therapy with the liposomal RNA interference therapeutic Atu027 combined with gemcitabine in patients with pancreatic adenocarcinoma. A randomized phase Ib/IIa study. Cancers. 2020;12:3130. doi: 10.3390/cancers12113130. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3390/cancers12113130\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7693593/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33114652/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Safety,%20efficacy%20and%20pharcacokinetics%20of%20targeted%20therapy%20with%20the%20liposomal%20RNA%20interference%20therapeutic%20Atu027%20combined%20with%20gemcitabine%20in%20patients%20with%20pancreatic%20adenocarcinoma.%20A%20randomized%20phase%20Ib/IIa%20study&amp;author=B%20Schultheis&amp;volume=12&amp;publication_year=2020&amp;pages=3130&amp;pmid=33114652&amp;doi=10.3390/cancers12113130&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR50\"> <span class=\"label\"> 50. </span> <cite> Strumberg D, et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J. Clin. Pharm. Ther. 2012;50:76\u201378. doi: 10.5414/cpp50076. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.5414/cpp50076\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22192654/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Int%20J.%20Clin.%20Pharm.%20Ther.&amp;title=Phase%20I%20clinical%20development%20of%20Atu027,%20a%20siRNA%20formulation%20targeting%20PKN3%20in%20patients%20with%20advanced%20solid%20tumors&amp;author=D%20Strumberg&amp;volume=50&amp;publication_year=2012&amp;pages=76-78&amp;pmid=22192654&amp;doi=10.5414/cpp50076&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR51\"> <span class=\"label\"> 51. </span> <cite> Browne CM, et al. A chemoproteomic strategy for direct and proteome-wide covalent inhibitor target-site identification. J. Am. Chem. Soc. 2019;141:191\u2013203. doi: 10.1021/jacs.8b07911. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/jacs.8b07911\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6487859/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/30518210/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Am.%20Chem.%20Soc.&amp;title=A%20chemoproteomic%20strategy%20for%20direct%20and%20proteome-wide%20covalent%20inhibitor%20target-site%20identification&amp;author=CM%20Browne&amp;volume=141&amp;publication_year=2019&amp;pages=191-203&amp;pmid=30518210&amp;doi=10.1021/jacs.8b07911&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR52\"> <span class=\"label\"> 52. </span> <cite> Asquith CRM, et al. Identification of 4-anilinoquin(az)oline as a cell-active protein kinase novel 3 (PKN3) inhibitor chemotype. Chem. Med. Chem. 2022;17:e202200161. doi: 10.1002/cmdc.202200161. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1002/cmdc.202200161\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC9233141/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/35403825/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Chem.%20Med.%20Chem.&amp;title=Identification%20of%204-anilinoquin(az)oline%20as%20a%20cell-active%20protein%20kinase%20novel%203%20(PKN3)%20inhibitor%20chemotype&amp;author=CRM%20Asquith&amp;volume=17&amp;publication_year=2022&amp;pages=e202200161&amp;pmid=35403825&amp;doi=10.1002/cmdc.202200161&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR53\"> <span class=\"label\"> 53. </span> <cite> Samaras P, et al. ProteomicsDB: a multi-omics and multi-organism resource for life science research. Nucleic Acids Res. 2019;48:D1153\u2013D1163. doi: 10.1093/nar/gkz974. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/nar/gkz974\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7145565/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31665479/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res.&amp;title=ProteomicsDB:%20a%20multi-omics%20and%20multi-organism%20resource%20for%20life%20science%20research&amp;author=P%20Samaras&amp;volume=48&amp;publication_year=2019&amp;pages=D1153-D1163&amp;pmid=31665479&amp;doi=10.1093/nar/gkz974&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR54\"> <span class=\"label\"> 54. </span> <cite> Johnson JL, et al. An atlas of substrate specificities for the human serine/threonine kinome. Nature. 2023;613:759\u2013766. doi: 10.1038/s41586-022-05575-3. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41586-022-05575-3\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC9876800/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/36631611/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=An%20atlas%20of%20substrate%20specificities%20for%20the%20human%20serine/threonine%20kinome&amp;author=JL%20Johnson&amp;volume=613&amp;publication_year=2023&amp;pages=759-766&amp;pmid=36631611&amp;doi=10.1038/s41586-022-05575-3&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR55\"> <span class=\"label\"> 55. </span> <cite> Lautenbacher L, et al. ProteomicsDB: toward a FAIR open-source resource for life-science research. Nucleic Acids Res. 2021;50:D1541\u2013D1552. doi: 10.1093/nar/gkab1026. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/nar/gkab1026\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8728203/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34791421/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res.&amp;title=ProteomicsDB:%20toward%20a%20FAIR%20open-source%20resource%20for%20life-science%20research&amp;author=L%20Lautenbacher&amp;volume=50&amp;publication_year=2021&amp;pages=D1541-D1552&amp;pmid=34791421&amp;doi=10.1093/nar/gkab1026&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR56\"> <span class=\"label\"> 56. </span> <cite> Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583\u2013589. doi: 10.1038/s41586-021-03819-2. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41586-021-03819-2\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8371605/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34265844/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Highly%20accurate%20protein%20structure%20prediction%20with%20AlphaFold&amp;author=J%20Jumper&amp;volume=596&amp;publication_year=2021&amp;pages=583-589&amp;pmid=34265844&amp;doi=10.1038/s41586-021-03819-2&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR57\"> <span class=\"label\"> 57. </span> <cite> Lemeer S, Z\u00f6rgiebel C, Ruprecht B, Kohl K, Kuster B. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity. J. Proteome Res. 2013;12:1723\u20131731. doi: 10.1021/pr301073j. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/pr301073j\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23495751/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Proteome%20Res.&amp;title=Comparing%20immobilized%20kinase%20inhibitors%20and%20covalent%20ATP%20probes%20for%20proteomic%20profiling%20of%20kinase%20expression%20and%20drug%20selectivity&amp;author=S%20Lemeer&amp;author=C%20Z%C3%B6rgiebel&amp;author=B%20Ruprecht&amp;author=K%20Kohl&amp;author=B%20Kuster&amp;volume=12&amp;publication_year=2013&amp;pages=1723-1731&amp;pmid=23495751&amp;doi=10.1021/pr301073j&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR58\"> <span class=\"label\"> 58. </span> <cite> R\u00f6hm S, et al. Fast iterative synthetic approach toward identification of novel highly selective p38 MAP kinase inhibitors. J. Med. Chem. 2019;62:10757\u201310782. doi: 10.1021/acs.jmedchem.9b01227. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1021/acs.jmedchem.9b01227\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31702918/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J.%20Med.%20Chem.&amp;title=Fast%20iterative%20synthetic%20approach%20toward%20identification%20of%20novel%20highly%20selective%20p38%20MAP%20kinase%20inhibitors&amp;author=S%20R%C3%B6hm&amp;volume=62&amp;publication_year=2019&amp;pages=10757-10782&amp;pmid=31702918&amp;doi=10.1021/acs.jmedchem.9b01227&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR59\"> <span class=\"label\"> 59. </span> <cite> Zecha J, et al. TMT labeling for the masses: a robust and cost-efficient, in-solution labeling approach. Mol. Cell. Proteom. 2019;18:1468\u20131478. doi: 10.1074/mcp.TIR119.001385. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1074/mcp.TIR119.001385\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6601210/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/30967486/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mol.%20Cell.%20Proteom.&amp;title=TMT%20labeling%20for%20the%20masses:%20a%20robust%20and%20cost-efficient,%20in-solution%20labeling%20approach&amp;author=J%20Zecha&amp;volume=18&amp;publication_year=2019&amp;pages=1468-1478&amp;pmid=30967486&amp;doi=10.1074/mcp.TIR119.001385&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"CR60\"> <span class=\"label\"> 60. </span> <cite> Ruprecht, B. et al. in <em> Proteomics: Methods and Protocols </em> (eds Comai, L. et al.) 47\u201360 (Springer, 2017). </cite> </li> <li id=\"CR61\"> <span class=\"label\"> 61. </span> <cite> Ruprecht, B., Zecha, J., Zolg, D. P. &amp; Kuster, B. in <em> Proteomics: Methods and Protocols </em> (eds Comai, L. et al.) 83\u201398 (Springer, 2017). </cite> </li> </ul> </section> </section> <section class=\"associated-data\" id=\"_ad93_\" lang=\"en\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"_ad93_-anchor\"> </a> Associated Data </h2> <p class=\"font-secondary\"> <em> This section collects any data citations, data availability statements, or supplementary materials included in this article. </em> </p> <section class=\"supplementary-materials\" id=\"_adsm93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Supplementary Materials </h3> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material1_reqid_\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM1_ESM.pdf\"> Reporting Summary </a> <sup> (1.6MB, pdf) </sup> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material2_reqid_\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM2_ESM.xlsx\"> <span> Supplementary Table 1 </span> </a> <sup> (665.1KB, xlsx) </sup> <p> Compound annotation. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material3_reqid_\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM3_ESM.xlsx\"> <span> Supplementary Table 2 </span> </a> <sup> (701.7KB, xlsx) </sup> <p> Drug matrix of target affinity values. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material4_reqid_\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM4_ESM.xlsx\"> <span> Supplementary Table 3 </span> </a> <sup> (2.1MB, xlsx) </sup> <p> Selectivities of tool compounds. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material5_reqid_\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM5_ESM.xlsx\"> <span> Supplementary Table 4 </span> </a> <sup> (56KB, xlsx) </sup> <p> Results related to CK2 follow-up experiments. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material6_reqid_\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM6_ESM.xlsx\"> <span> Supplementary Table 5 </span> </a> <sup> (13.4MB, xlsx) </sup> <p> Results related to PKN3 follow-up experiments. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material7_reqid_\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM7_ESM.pdf\"> <span> Source Data Fig. 3 </span> </a> <sup> (4.6MB, pdf) </sup> <p> Unprocessed western blots. </p> </div> </div> </section> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material8_reqid_\"> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11062922/bin/41589_2023_1459_MOESM8_ESM.pdf\"> <span> Source Data Extended Data Fig. 4 </span> </a> <sup> (10.3MB, pdf) </sup> <p> Unprocessed western blots. </p> </div> </div> </section> </section> <section class=\"data-availability-statement\" id=\"_adda93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Data Availability Statement </h3> <p> The proteomic data, including the UniProt reference database, are available at the ProteomeXchange Consortium ( <a class=\"usa-link usa-link--external\" href=\"http://proteomecentral.proteomexchange.org\" rel=\"noopener noreferrer\" target=\"_blank\"> http://proteomecentral.proteomexchange.org </a> ) via the MassIVE partner repositories with the data set identifier <a class=\"usa-link usa-link--external\" href=\"https://massive.ucsd.edu/ProteoSAFe/QueryMSV?id=MSV000092248\" rel=\"noopener noreferrer\" target=\"_blank\"> MSV000092248 </a> , as well as at ProteomicsDB ( <a class=\"usa-link usa-link--external\" href=\"http://www.proteomicsdb.org\" rel=\"noopener noreferrer\" target=\"_blank\"> www.proteomicsdb.org </a> ). Crystal structure coordinates and structure factors have been deposited to PDB under accession numbers <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWE/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWE </a> , <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7A4Q/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7A4Q </a> and <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2210/pdb7ZWG/pdb\" rel=\"noopener noreferrer\" target=\"_blank\"> 7ZWG </a> . <a class=\"usa-link\" href=\"#Sec27\"> Source data </a> are provided with this paper. </p> </section> </section> </section> <footer class=\"p courtesy-note font-secondary font-sm text-center\"> <hr class=\"headless\"/> <p> Articles from Nature Chemical Biology are provided here courtesy of <strong> Nature Publishing Group </strong> </p> </footer> </section> </article> </main> </div> </div> </div> <div class=\"pmc-sidenav desktop:grid-col-4 display-flex\"> <section aria-label=\"Article resources and navigation\" class=\"pmc-sidenav__container\"> <button class=\"usa-button pmc-sidenav__container__close usa-button--unstyled\" type=\"button\"> <img alt=\"Close\" role=\"img\" src=\"/static/img/usa-icons/close.svg\"/> </button> <div class=\"display-none desktop:display-block\"> <section class=\"margin-top-4 desktop:margin-top-0\"> <h2 class=\"margin-top-0\"> ACTIONS </h2> <ul class=\"usa-list usa-list--unstyled usa-list--actions\"> <li> <a class=\"usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"https://doi.org/10.1038/s41589-023-01459-3\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 padding-right-2\"> View on publisher site </span> </a> </li> <li> <a class=\"usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"pdf/41589_2023_Article_1459.pdf\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> PDF (15.3 MB) </span> </a> </li> <li> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1\" role=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Cite </span> </button> </li> <li> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> Collections </span> </button> </li> <li class=\"pmc-permalink\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Permalink </span> </button> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11062922/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </section> </div> <section class=\"pmc-resources margin-top-6 desktop:margin-top-4\"> <h2 class=\"margin-top-0\"> RESOURCES </h2> <div class=\"usa-accordion usa-accordion--multiselectable\"> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-similar-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Similar articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-similar-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-cited-by-other-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Cited by other articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-cited-by-other-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-links-to-ncbi-databases\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Links to NCBI Databases </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-links-to-ncbi-databases\"> </div> </div> </section> <section class=\"usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4\"> <nav aria-label=\"On this page\" class=\"usa-in-page-nav__nav\"> <h2 class=\"usa-in-page-nav__heading\" tabindex=\"0\"> On this page </h2> <ul class=\"usa-in-page-nav__list\"> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#Abs1\"> Abstract </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#Sec1\"> Main </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#Sec2\"> Results </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#Sec8\"> Discussion </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#Sec9\"> Methods </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#Sec24\"> Online content </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#ack1\"> Acknowledgements </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#notes1\"> Author contributions </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#notes2\"> Peer review </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#notes3\"> Data availability </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#FPar4\"> Competing interests </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#fn-group1\"> Footnotes </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#Bib1\"> References </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#_ad93_\"> Associated Data </a> </li> </ul> </nav> </section> </section> </div> <div aria-label=\"Citation Dialog\" class=\"overlay citation-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog citation-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Cite </h2> <button class=\"usa-button usa-button--unstyled close-overlay text-black width-auto\" tabindex=\"1\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"citation-text-block\"> <div class=\"citation-text margin-bottom-2\"> </div> <ul class=\"usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center\"> <li> <button class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus\" tabindex=\"2\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span> Copy </span> </button> </li> <li> <a class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button\" href=\"#\" role=\"button\" tabindex=\"3\" title=\"Download a file for external citation management software\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-none mobile-lg:display-inline\"> Download .nbib </span> <span class=\"display-inline mobile-lg:display-none\"> .nbib </span> </a> </li> <li> <div class=\"display-inline-flex flex-align-center\"> <label class=\"usa-label margin-top-0\"> Format: </label> <select aria-label=\"Format\" class=\"usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4\" tabindex=\"4\"> <option value=\"AMA\"> AMA </option> <option value=\"APA\"> APA </option> <option value=\"MLA\"> MLA </option> <option selected=\"selected\" value=\"NLM\"> NLM </option> </select> </div> </li> </ul> <div class=\"dots-loading-indicator citation-loading-indicator\"> <div class=\"dot dot-1\"> </div> <div class=\"dot dot-2\"> </div> <div class=\"dot dot-3\"> </div> </div> </div> </div> </div> <div class=\"overlay collections-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog collections-dialog\" id=\"collections-action-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Add to Collections </h2> </div> <div class=\"collections-action-panel action-panel\"> <form class=\"usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors\" id=\"collections-action-dialog-form\"> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"usa-radio\"> <input class=\"usa-radio__input usa-radio__input--tile collections-new margin-top-0\" id=\"collections-action-dialog-new\" name=\"collections\" type=\"radio\" value=\"new\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-new\"> Create a new collection </label> </div> <div class=\"usa-radio\"> <input checked=\"true\" class=\"usa-radio__input usa-radio__input--tile collections-existing\" id=\"collections-action-dialog-existing\" name=\"collections\" type=\"radio\" value=\"existing\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-existing\"> Add to an existing collection </label> </div> </fieldset> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"action-panel-control-wrap new-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-new\"> Name your collection <abbr class=\"usa-hint usa-hint--required text-no-underline\" title=\"required\"> * </abbr> </label> <input class=\"usa-input collections-action-add-to-new\" id=\"collections-action-dialog-add-to-new\" maxlength=\"\" name=\"add-to-new-collection\" pattern='[^\"&amp;=&lt;&gt;/]*' required=\"\" title='The following characters are not allowed in the Name field: \"&amp;=&lt;&gt;/' type=\"text\"/> </div> <div class=\"action-panel-control-wrap existing-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-existing\"> Choose a collection </label> <select class=\"usa-select collections-action-add-to-existing\" id=\"collections-action-dialog-add-to-existing\"> </select> <div class=\"collections-retry-load-on-error usa-input-error-message selection-validation-message\"> Unable to load your collection due to an error <br/> <a href=\"#\"> Please try again </a> </div> </div> </fieldset> <div class=\"display-inline-flex\"> <button class=\"usa-button margin-top-0 action-panel-submit\" type=\"submit\"> Add </button> <button aria-label=\"Close 'Add to Collections' panel\" class=\"usa-button usa-button--outline margin-top-0 action-panel-cancel\" ref=\"linksrc=close_collections_panel\"> Cancel </button> </div> </form> </div> </div> </div> </div> </div> </div> <footer class=\"ncbi-footer ncbi-dark-background\"> <div class=\"ncbi-footer__icon-section\"> <div class=\"ncbi-footer__social-header\"> Follow NCBI </div> <div class=\"grid-container ncbi-footer__ncbi-social-icons-container\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://twitter.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"40\" viewbox=\"0 0 40 40\" width=\"40\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.facebook.com/ncbi.nlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"29\" viewbox=\"0 0 16 29\" width=\"16\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.linkedin.com/company/ncbinlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"23\" viewbox=\"0 0 26 24\" width=\"25\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z\"> </path> <path d=\"M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z\"> </path> <path d=\"M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on LinkedIn </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://github.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"27\" viewbox=\"0 0 28 28\" width=\"28\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on GitHub </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://ncbiinsights.ncbi.nlm.nih.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"26\" viewbox=\"0 0 27 27\" width=\"26\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z\"> </path> <path d=\"M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z\"> </path> <path d=\"M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI RSS feed </span> </a> </div> </div> <div class=\"grid-container ncbi-footer__container\"> <div class=\"grid-row ncbi-footer__main-content-container\"> <div class=\"ncbi-footer__column\"> <p class=\"ncbi-footer__circled-icons-heading\"> Connect with NLM </p> <div class=\"ncbi-footer__circled-icons-list\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://twitter.com/nlm_nih\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"32\" viewbox=\"0 0 40 40\" width=\"32\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.facebook.com/nationallibraryofmedicine\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"24\" viewbox=\"0 0 13 24\" width=\"13\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.youtube.com/user/NLMNIH\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"15\" viewbox=\"0 0 21 15\" width=\"21\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z\" fill=\"white\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on YouTube </span> </a> </div> </div> <address class=\"ncbi-footer__address ncbi-footer__column\"> <p> <a class=\"usa-link usa-link--external\" href=\"https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323\" rel=\"noopener noreferrer\" target=\"_blank\"> National Library of Medicine <br/> 8600 Rockville Pike <br/> Bethesda, MD 20894 </a> </p> </address> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/web_policies.html\"> Web Policies </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office\"> FOIA </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/vulnerability-disclosure-policy/index.html\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS Vulnerability Disclosure </a> </li> </ul> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://support.nlm.nih.gov/?pagename=cloudpmc-viewer%3Apmc%3Aarticle%3Ajournal\"> Help </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/accessibility.html\"> Accessibility </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/careers/careers.html\"> Careers </a> </li> </ul> </div> <div class=\"grid-row grid-col-12\"> <ul class=\"ncbi-footer__bottom-links-list\"> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/\"> NLM </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/\"> NIH </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.usa.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> USA.gov </a> </li> </ul> </div> </div> </footer> <div id=\"ZN_dikYWqsjiUWN0Q5\"> </div> <button class=\"back-to-top\"> <label> Back to Top </label> <svg aria-hidden=\"true\" class=\"usa-icon order-0\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#arrow_upward\"> </use> </svg> </button> <div class=\"fake-body-scroll\"> </div> <div class=\"fake-body-scroll\"> </div> <div class=\"QSIFeedbackButton\"> <button aria-label=\"Tell us what you think!\" id=\"QSIFeedbackButton-btn\" role=\"button\"> <img alt=\"Tell us what you think!\" src=\"https://iad1.qualtrics.com/WRQualtricsSiteIntercept/Graphic.php?IM=IM_3xWqwNkIHc7cA0S\"/> </button> </div> </body> </html>) and a list of known data repositories (bigd.big.ac.cn, massive.ucsd.edu, www.ebi.ac.uk, www.iprox.cn, proteomecentral.proteomexchange.org, www.proteomexchange.org, pdc.cancer.gov, doi.org, www.ncbi.nlm.nih.gov). Given this information, please return a JSON array of objects where each object has the following structure:\n- `dataset_identifier`: The dataset identifier (a code). If not found, set it to \"n/a\".\n- `repository_reference`: The URL or reference to the data repository. If not found, set it to \"n/a\".\n\nPlease follow these strict instructions:\n- The output must be a valid JSON array of objects.\n- Each object must contain the keys `dataset_identifier` and `repository_reference`.\n- Any other output format will be considered invalid."}]}]